U.S. patent application number 13/196885 was filed with the patent office on 2015-06-18 for method of determining clonotypes and clonotype profiles.
This patent application is currently assigned to Sequenta, Inc.. The applicant listed for this patent is Malek Faham, Martin Moorhead, Thomas Willis. Invention is credited to Malek Faham, Martin Moorhead, Thomas Willis.
Application Number | 20150167080 13/196885 |
Document ID | / |
Family ID | 53176440 |
Filed Date | 2015-06-18 |
United States Patent
Application |
20150167080 |
Kind Code |
A1 |
Moorhead; Martin ; et
al. |
June 18, 2015 |
METHOD OF DETERMINING CLONOTYPES AND CLONOTYPE PROFILES
Abstract
The invention is directed to methods for determining clonotypes
and clonotype profiles in assays for analyzing immune repertoires
by high throughput nucleic acid sequencing of somatically
recombined immune molecules. In one aspect, the invention comprises
generating a clonotype profile from an individual by generating
sequence reads from a sample of recombined immune molecules;
forming from the sequence reads a sequence tree representing
candidate clonotypes each having a frequency; coalescing with a
highest frequency candidate clonotype any lesser frequency
candidate clonotypes whenever such lesser frequency is below a
predetermined value and whenever a sequence difference therebetween
is below a predetermined value to form a clonotype. After such
coalescence, the candidate clonotypes is removed from the sequence
tree and the process is repeated. This approach permits rapid and
efficient differentiation of candidate clonotypes with genuine
sequence differences from those with experimental or measurement
errors, such as sequencing errors.
Inventors: |
Moorhead; Martin; (San
Mateo, CA) ; Faham; Malek; (Pacifica, CA) ;
Willis; Thomas; (San Francisco, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Moorhead; Martin
Faham; Malek
Willis; Thomas |
San Mateo
Pacifica
San Francisco |
CA
CA
CA |
US
US
US |
|
|
Assignee: |
Sequenta, Inc.
San Francisco
CA
|
Family ID: |
53176440 |
Appl. No.: |
13/196885 |
Filed: |
August 2, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13100389 |
May 4, 2011 |
8691510 |
|
|
13196885 |
|
|
|
|
12615263 |
Nov 9, 2009 |
8236503 |
|
|
13100389 |
|
|
|
|
61446822 |
Feb 25, 2011 |
|
|
|
61455743 |
Oct 25, 2010 |
|
|
|
Current U.S.
Class: |
506/2 ;
702/20 |
Current CPC
Class: |
C12Q 1/6881 20130101;
C12Q 2600/158 20130101; G16B 10/00 20190201; C12Q 2600/156
20130101; G16B 30/00 20190201; C12Q 2600/16 20130101; C12Q 1/6883
20130101 |
International
Class: |
C12Q 1/68 20060101
C12Q001/68; C40B 20/00 20060101 C40B020/00 |
Claims
1. A method of determining clonotypes of an immune repertoire, said
method comprising the steps: obtaining from a subject a sample
comprising T-cells and/or B-cells; spatially isolating on a solid
surface individual molecules of recombined nucleic acids encoding T
cell receptor molecules or immunoglobulin molecules from said
T-cells and/or B-cells of the sample; sequencing by synthesis using
reversibly terminated labeled nucleotides said spatially isolated
individual molecules of recombined nucleic acids to generate a set
of sequence reads, said molecules of recombined nucleic acids each
having a V region, an NDN region and a J region, wherein clonotypes
are formed from said set of sequence reads by: (a) constructing
from sequence reads encompassing at least a portion of an NDN
region a sequence tree having leaves representing candidate
clonotypes, each leaf and its corresponding candidate clonotype
having a frequency; (b) coalescing with a highest frequency
candidate clonotype any lesser frequency candidate clonotype
whenever a lesser frequency of said lesser frequency candidate
clonotype is below a predetermined frequency value and a sequence
difference therebetween is below a predetermined difference value
to form a clonotype having a sequence of said highest frequency
candidate clonotype and having associated sequence reads summed
from said highest frequency candidate clonotype and said lesser
frequency candidate clonotype; (c) removing leaves corresponding to
said coalesced candidate clonotypes from said sequence tree; and
(d)repeating steps (b) and (c) until a highest frequency of a
lesser frequency candidate clonotype is below a predetermined
stopping value, thereby determining clonotypes from said
sample.
2. The method of claim 1 wherein said predetermined difference
value is a predetermined Hamming distance.
3. The method of claim 1 wherein said predetermined difference
value of said sequence difference is a non-increasing function of
how many times said steps (b) and (c) have been repeated.
4. The method of claim 1 wherein said predetermined difference
value of said sequence difference is a non-increasing function of
said frequency of said highest frequency candidate clonotype.
5. The method of claim 1 wherein said sequence difference between
said highest frequency candidate clonotype and said lesser
frequency candidate clonotype comprises differences at one or more
nucleotide locations, and wherein said highest frequency candidate
clonotype is coalesced with any said lesser frequency candidate
clonotype to form said clonotype whenever a function depending on
frequencies of said highest frequency candidate clonotype, said
lesser frequency candidate clonotype, said sequence difference and
quality scores of said one or more nucleotide locations is greater
than a predetermined coalescence value, wherein said function (i)
monotonically increases with increasing ratio of frequency of said
highest frequency candidate clonotype and frequency of said lesser
frequency candidate clonotype, (ii) monotonically decreases with
increasing sequence difference between said highest frequency
candidate clonotype and said lesser frequency candidate clonotype,
and (iii) monotonically decreases with increasing quality scores of
said one or more nucleotide locations.
6. The method of claim 5 wherein said function monotonically
decreases with an average of quality scores of said one or more
nucleotide locations.
7. The method of claim 1 further including a step of aligning said
sequence reads encompassing portions of said V regions and portions
of said J regions to V and J region references respectively to
determine said V and J regions of said molecules of recombined
nucleic acids.
8. The method of claim 7 wherein said step of aligning includes
aligning said sequence reads encompassing said portions of said V
regions to a sequence tree of said V region references and aligning
said sequence reads encompassing said portions of said J regions to
a sequence tree of said J region references.
9. The method of claim 1 wherein for each of said molecules at
least one sequence read encompasses said NDN region and portions of
adjoining V and J regions thereof
10. The method of claim 1 further including prior to said step of
coalescing a step of identifying for each said highest frequency
candidate clonotype selected all said lesser frequency candidate
clonotype having a sequence difference therebetween less than said
predetermined difference value.
11. The method of claim 10 wherein said step of identifying
includes comparing said highest frequency candidate clonotype
selected with every lesser frequency candidate clonotype using
dynamic programming.
12. The method of claim 11 wherein said comparing is carried out by
banded dynamic programming.
13. The method of claim 1 wherein said sequence difference includes
differences due to nucleotide substitutions, insertions and
deletions.
14. The method of claim 1 wherein said set of sequence reads
comprises at least 1000 sequence reads of at least 30 nucleotides
in length.
15. The method of claim 1 wherein said predetermined stopping value
is a frequency corresponding to a singleton lesser frequency
candidate clonotype, or a frequency corresponding to a single
lymphocyte.
16. A method of determining clonotypes of an immune repertoire,
said method comprising the steps: obtaining from a subject a sample
comprising T-cells and/or B-cells; spatially isolating on a solid
surface individual molecules of recombined nucleic acids encoding T
cell receptor molecules or immunoglobulin molecules from said
T-cells and/or B-cells; sequencing by synthesis using reversibly
terminated labeled nucleotides said spatially isolated individual
molecules of recombined nucleic acids to generate a set of sequence
reads, said molecules of recombined nucleic acids each having
portions of a V region, an NDN region and a J region wherein
clonotypes are formed from said set of sequence reads by: (a)
constructing from sequence reads encompassing portions of NDN
regions a sequence tree having leaves representing candidate
clonotypes, each leaf and its corresponding candidate clonotype
having a frequency; (b) selecting a highest frequency candidate
clonotype and identifying all lesser frequency candidate clonotype
having a sequence difference therewith less than a predetermined
difference value to form a coalescence subset; (c) coalescing with
said highest frequency candidate clonotype any lesser frequency
candidate clonotype in said coalescence subset whenever a lesser
frequency of said lesser frequency candidate clonotype is below a
predetermined frequency value to form a clonotype having a sequence
of said highest frequency candidate clonotype and having associated
sequence reads summed from said highest frequency candidate
clonotype and said lesser frequency candidate clonotype;
(d)removing leaves corresponding to said coalesced candidate
clonotypes from said sequence tree; and (e) repeating steps (b)
through (d) until clonotypes have been formed from all
non-singleton lesser frequency candidate clonotypes, thereby
determining clonotypes from said sample.
17. The method of claim 16 wherein said predetermined difference
value is a predetermined Hamming distance.
18. The method of claim 16 wherein said predetermined difference
value of said sequence difference is a non-increasing function of
said frequency of said highest frequency candidate clonotype.
19. The method of claim 16 wherein said sequence difference between
said highest frequency candidate clonotype and said lesser
frequency candidate clonotype comprises differences at one or more
nucleotide locations, and wherein said highest frequency candidate
clonotype is coalesced with any said lesser frequency candidate
clonotype to form said clonotype whenever a function depending on
frequencies of said highest frequency candidate clonotype, said
lesser frequency candidate clonotype, said sequence difference and
quality scores of said one or more nucleotide locations is greater
than a predetermined coalescence value, wherein said function (i)
monotonically increases with increasing ratio of frequency of said
highest frequency candidate clonotype and frequency of said lesser
frequency candidate clonotype, (ii) monotonically decreases with
increasing sequence difference between said highest frequency
candidate clonotype and said lesser frequency candidate clonotype,
and (iii) monotonically decreases with increasing quality scores of
said one or more nucleotide locations.
20. The method of claim 19 wherein said function monotonically
decreases with an average of quality scores of said one or more
nucleotide locations.
21. The method of claim 16 wherein for each of said molecules at
least one sequence read encompasses said NDN region and portions of
adjoining V and J regions thereof.
22. A method of generating a clonotype profile from an individual,
said method comprising the steps of: (a) spatially isolating on a
solid surface individual molecules of recombined nucleic acids from
a sample containing T-cells and/or B-cells of said individual,
wherein said recombined nucleic acids encode T cell receptor
molecules or immunoglobulin molecules; (b) sequencing by synthesis
using reversibly terminated labeled nucleotides said spatially
isolated individual molecules to produce a plurality of sequence
reads each having portions of a V region, an NDN region and a J
region and forming from sequence reads encompassing an NDN region a
sequence tree having leaves representing candidate clonotypes, each
leaf and its corresponding candidate clonotype having a frequency;
(c) coalescing with a highest frequency candidate clonotype any
lesser frequency candidate clonotype whenever a lesser frequency of
said lesser frequency candidate clonotype is below a predetermined
frequency value and a sequence difference therebetween is below a
predetermined difference value to form a clonotype having a
sequence of said highest frequency candidate clonotype and having
associated sequence reads summed from said highest frequency
candidate clonotype and said lesser frequency candidate clonotype
and wherein such coalesced lesser frequency candidate clonotype is
thereafter disregarded; and (d) repeating step (c) until clonotypes
have been formed from all non-singleton lesser frequency candidate
clonotypes, thereby generating said clonotype profile.
23. The method of claim 22 wherein said predetermined difference
value is a predetermined Hamming distance.
24. The method of claim 22 wherein said predetermined difference
value of said sequence difference is a non-increasing function of
said frequency of said highest frequency candidate clonotype.
25. The method of claim 22 wherein said sequence difference between
said highest frequency candidate clonotype and said lesser
frequency candidate clonotype comprises differences at one or more
nucleotide locations, and wherein said highest frequency candidate
clonotype is coalesced with any said lesser frequency candidate
clonotype to form said clonotype whenever a function depending on
frequencies of said highest frequency candidate clonotype, said
lesser frequency candidate clonotype, said sequence difference and
quality scores of said one or more nucleotide locations is greater
than a predetermined coalescence value, wherein said function (i)
monotonically increases with increasing ratio of frequency of said
highest frequency candidate clonotype and frequency of said lesser
frequency candidate clonotype, (ii) monotonically decreases with
increasing sequence difference between said highest frequency
candidate clonotype and said lesser frequency candidate clonotype,
and (iii) monotonically decreases with increasing quality scores of
said one or more nucleotide locations.
26. The method of claim 25 wherein said function monotonically
decreases with an average of quality scores of said one or more
nucleotide locations.
27. The method of claim 22 further including a step of aligning
said sequence reads encompassing portions of said V regions and
portions of said J regions to V and J region references
respectively to determine said V and J regions of said recombined
nucleic acids.
28. The method of claim 27 wherein said step of aligning includes
aligning said sequence reads encompassing said portions of said V
regions to a sequence tree of said V region references and aligning
said sequence reads encompassing said portions of said J regions to
a sequence tree of said J region references.
29. The method of claim 22 wherein for each of said molecules at
least one sequence read encompasses said NDN region and portions of
adjoining V and J regions thereof
30-35. (canceled)
36. The method of claim 1 further comprising a step of amplifying
said molecules of recombined nucleic acids from said sample.
37. The method of claim 36 wherein said sample comprises at least
10,000 T cells and wherein said recombined nucleic acids encode a
TCR.beta. chain or a portion thereof.
38. The method of claim 36 wherein said sample comprises at least
10,000 B cells and wherein said recombined nucleic acids encode an
IgH chain or a portion thereof
39. The method of claim 36 wherein said sequence reads each have a
length in a range of from 20 to 400 nucleotides.
40. The method of claim 36 wherein said sample is a blood
sample.
41. The method of claim 36 wherein said sequence reads each have a
length less than 300 bp.
42. The method of claim 16 further comprising a step of amplifying
said molecules of recombined nucleic acids from said sample.
43. The method of claim 16 wherein said sample comprises at least
10,000 T cells and wherein said recombined nucleic acids encode a
TCR.beta. chain or a portion thereof.
44. The method of claim 16 wherein said sample comprises at least
10,000 B cells and wherein said recombined nucleic acids encode an
IgH chain or a portion thereof
45. The method of claim 16 wherein said sample is a blood
sample.
46. The method of claim 16 wherein said sequence reads each have a
length less than 300 bp.
47. The method of claim 22 further comprising a step of amplifying
said molecules of recombined nucleic acids from said sample.
48. The method of claim 22 wherein said sample comprises at least
10,000 T cells and wherein said recombined nucleic acids encode a
TCR.beta. chain or a portion thereof.
49. The method of claim 22 wherein said sample comprises at least
10,000 B cells and wherein said recombined nucleic acids encode an
IgH chain or a portion thereof.
50. The method of claim 22 wherein said sample is a blood
sample.
51. The method of claim 22 wherein said sequence reads each have a
length less than 300 bp.
Description
[0001] This application is a continuation-in-part of copending U.S.
application Ser. No. 13/100,389 filed 4 May 2011, which is a
continuation-in-part of copending U.S. application Ser. No.
12/615,263 filed 9 Nov. 2009, and this application claims benefit
of U.S. provisional applications 61/446,822 filed 25 Feb. 2011 and
61/455,743 filed 25 Oct. 2010, the foregoing applications being
incorporated by reference in their entireties.
BACKGROUND OF THE INVENTION
[0002] Analysis of biological or medical samples often requires the
determination of nucleic acid sequences of large and complex
populations of DNA and/or RNA, e.g. Gloor et al, PLoS ONE 5(10): el
5406 (2010); Petrosino et al, Clinical Chemistry, 55(5): 856-866
(2009); Arstila et al, Science, 286: 958-961 (1999). In particular,
profiles of nucleic acids encoding immune molecules, such as T cell
or B cell receptors, or their components, contain a wealth of
information on the state of health or disease of an organism, so
that the use of such profiles as diagnostic or prognostic
indicators has been proposed for a wide variety of conditions, e.g.
Faham and Willis, U.S. patent publication 2010/0151471; Freeman et
al, Genome Research, 19: 1817-1824 (2009); Boyd et al, Sci. Transl.
Med., 1(12): 12ra23 (2009); He et al, Oncotarget (Mar. 8, 2011).
Such sequence-based profiles arc capable of much greater
sensitivity than approaches based on size distributions of
amplified target nucleic acids, sequence sampling by microarrays,
hybridization kinetics curves from PCR amplicons, or other
approaches, e.g. Morley et al, U.S. Pat. No. 5,418,134; van Dongen
et al, Leukemia, 17: 2257-2317 (2003); Ogle ct al, Nucleic Acids
Research, 31: e139 (2003); Wang et al, BMC Genomics, 8: 329 (2007);
Baum et al, Nature Methods, 3(11): 895,901 (2006). However, the
efficient determination of clonotypes and clonotype profiles from
sequence data poses challenges because of the size populations to
be analyzed, the limited predictability of natural variability in
the sequences extracted from samples, and noise introduced into the
data by a host of sample preparation and measurement steps, e.g.
Warren et al, Genome Research, 21(5): 790-797 (2011).
[0003] In view of the potential importance of clonotype profiles
for diagnostic and prognostic applications, it would be
advantageous to many fields in medicine and biology, if methods
were available for overcoming drawbacks of current methodologies
for determining clonotypes and clonotype profiles from sequence
data.
SUMMARY OF THE INVENTION
[0004] The present invention is drawn to methods for producing
sequence-based profiles of complex nucleic acid populations. The
invention is exemplified in a number of implementations and
applications, some of which are summarized below and throughout the
specification.
[0005] In one aspect, the invention is directed to a method of
forming a clonotype profile comprising the steps of (a) forming a
data structure of somatically recombined immune molecules from
sequence reads thereof, (b) coalescing with a highest frequency
candidate clonotype any lesser frequency candidate clonotypes
whenever such lesser frequency is below a predetermined frequency
value and a sequence difference therebetween is below a
predetermined difference value to form a clonotype, (c) removing
the coalesced candidate clonotype from the data structure, and (d)
repeating steps (b) and (c) until a clonotype profile is formed. In
one aspect, such data structure is a sequence tree.
[0006] In another aspect, the invention is directed to a method of
generating a clonotype profile from an individual comprising the
steps of: (a) spatially isolating individual molecules derived from
a nucleic acid sample from T-cells and/or B-cells of the
individual; (b) sequencing said spatially isolated individual
molecules to produce a plurality of sequence reads each having
portions old V region, an NDN region and a J region wherein for
each such molecule at least one sequence lead encompasses a portion
of the NDN region (c) forming from sequence reads encompassing at
least a portion of an NDN region a data structure having elements
representing candidate clonotypes, each element and its
corresponding candidate clonotype having a frequency; (d)
coalescing with a highest frequency candidate clonotype any lesser
frequency candidate clonotypes whenever such lesser frequency is
below a predetermined frequency value and a sequence difference
therebetween is below a predetermined difference value to form a
clonotype having a sequence of the highest frequency candidate
clonotype; (e) removing elements corresponding to the coalesced
candidate clonotypes from the data structure; and (f) repeating
steps (d) and (e) until clonotypes have been formed from all
non-singleton lesser frequency candidate clonotypes, thereby
generating the clonotype profile. In one aspect, the data structure
is a sequence tree and the elements corresponding to candidate
clonotypes are leaves of the sequence tree.
[0007] In another aspect, the invention provides a method for
determining clonotypes of an immune repertoire comprising the
steps: (a) providing a set of sequence reads from a repertoire of
recombined immune molecules each having a V region, an NDN region
and a J region wherein for each such molecule at least one sequence
read encompasses at least a portion of the NDN region of such
molecule; (b) forming from sequence reads encompassing at least a
portion of an NDN region a data structure having elements
representing candidate clonotypes, each leaf and its corresponding
candidate clonotype having a frequency; (c) coalescing with a
highest frequency candidate clonotype any lesser frequency
candidate clonotypes whenever such lesser frequency is below a
predetermined frequency value and a sequence difference
therebetween is below a predetermined difference value to form a
clonotype having a sequence of the highest frequency candidate
clonotype; (d) removing elements corresponding to the coalesced
candidate clonotypes from the data structure; and (e) repeating
steps (c) and (d) until a highest frequency of a lesser frequency
candidate clonotype is below a predetermined stopping value. In one
aspect, the data structure is a sequence tree and the elements
corresponding to candidate clonotypes are leaves of the sequence
tree.
[0008] In still another aspect, the invention is directed to a
method of determining clonotypes of an immune repertoire comprising
the steps: (a) providing a set of sequence reads from a repertoire
of recombined immune molecules each having portions of a V region,
an NDN region and a J region wherein for each such molecule at
least one sequence read encompasses a portion of the NDN region of
such molecule; (b) forming from sequence reads encompassing
portions of NDN regions a sequence tree having leaves representing
candidate clonotypes, each leaf and its corresponding candidate
clonotype having a frequency; (c) selecting a highest frequency
candidate clonotype and identifying all said lesser frequency
candidate clonotypes having a sequence difference therewith less
than a predetermined difference value to form a coalescence subset;
(d) coalescing with the highest frequency candidate clonotype any
lesser frequency candidate clonotypes in the coalescence subset
whenever such lesser frequency is below a predetermined frequency
value to form a clonotype having a sequence of the highest
frequency candidate clonotype; (e) removing leaves corresponding to
the coalesced candidate clonotypes from the sequence tree; and (f)
repeating steps (c) and (c) until clonotypes have been formed from
all non-singleton lesser frequency candidate clonotypes.
[0009] The present invention provides methods for determining
clonotypes and clonotype profiles from large sets of sequence data
obtained by high throughput sequencing Of somatically recombined
immune molecules. In one aspect, the invention implements the above
methods by using one or more sequence trees for efficiently
carrying out sequence comparisons necessary for distinguishing
candidate clonotypes with genuine sequence differences from those
with experimental or measurement errors, such as sequencing
errors.
[0010] These above-characterized aspects, as well as other aspects,
of the present invention are exemplified in a number of illustrated
implementations and applications, some of which are shown in the
figures and characterized in the claims section that follows.
However, the above summary is not intended to describe each
illustrated embodiment or every implementation of the
invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0011] The novel features of the invention are set forth with
particularity in the appended claims. A better understanding of the
features and advantages of the present invention is obtained by
reference to the following detailed description that sets forth
illustrative embodiments, in which the principles of the invention
are utilized, and the accompanying drawings of which:
[0012] FIG. 1A illustrates an IgH transcript and sources of natural
variability within it.
[0013] FIG. 1B illustrates concepts of clonotypes in sequence space
and distances between closely related clonotypes.
[0014] FIG. 1C is a flow chart illustrating one embodiment of a
method for distinguishing genuinely different clonotypes from
clonotypes that differ solely by sequencing errors (which should be
coalesced).
[0015] FIG. 1D illustrates the form of a numerical function used in
one embodiment for determining whether or not to coalesce related
clonotypes.
[0016] FIGS. 1E-1F illustrate the use of sequence trees in the
methods of the invention.
[0017] FIGS. 2A-2B show a two-staged PCR scheme for amplifying
TCR.beta. genes.
[0018] FIG. 3A illustrates a PCR product to be sequenced that was
amplified using the scheme of FIGS. 2A-2B. FIG. 3B illustrates
details of determining a nucleotide sequence of the PCR product of
FIG. 3A. FIG. 3C illustrates details of another embodiment of
determining a nucleotide sequence of the PCR product of FIG.
3A.
[0019] FIG. 4A illustrates a PCR scheme for generating three
sequencing templates from an IgH chain in a single reaction. FIGS.
4B-4C illustrates a PCR scheme for generating three sequencing
templates from an IgH chain in three separate reactions after which
the resulting amplicons are combined for a secondary PCR to add P5
and P7 primer binding sites. FIG. 4D illustrates the locations of
sequence reads generated for an IgH chain. FIG. 4E illustrates the
use of the codon stricture of V and J regions to improve base calls
in the NDN region.
DETAILED DESCRIPTION OF THE INVENTION
[0020] The practice of the present invention may employ, unless
otherwise indicated, conventional techniques and descriptions of
molecular biology (including recombinant techniques),
bioinformatics, cell biology, and biochemistry, which are within
the skill of the art. Such conventional techniques include, but are
not limited to, sampling and analysis of blood cells, nucleic acid
sequencing and analysis, and the like. Specific illustrations of
suitable techniques can be had by reference to the example herein
below. However, other equivalent conventional procedures can, of
course, also be used. Such conventional techniques and descriptions
can be found in standard laboratory manuals such as Genome
Analysis: A Laboratory Manual Series (Vols. I-IV); PCR Primer: A
Laboratory Manual; and Molecular Cloning: A Laboratory Manual (all
from Cold Spring Harbor Laboratory Press); Gusfield, Algorithms on
Strings, Trees, and Sequences (Cambridge University Press, 1997);
and the like.
[0021] In one aspect, the invention is directed to a method for
obtaining and analyzing sequence data from a repertoire of immune
molecules, such as T cell receptors (TCRs), to rapidly and
efficiently determine a clonotype profile. Sequence data typically
comprises a large collection of sequence reads, i.e. sequences of
base calls and associated quality scores. A key challenge in
constructing clonotype profiles is to rapidly and accurately
distinguish sequence reads that contain genuine differences from
those that contain errors from non-biological sources, such as the
sequencing chemistry, amplification chemistry, or the like. An
aspect of the invention is the use of sequence trees to represent
and organize sequence data from immune molecules extracted from a
sample. Such immune molecules typically form an immune repertoire
which comprises a very laree set of very similar polynucleotides
(e.g. >1000, but more usually from 100,000 to 1,000,000, or
more) which arc relatively short in length (e.g. usually less than
300 bp). In one aspect of the invention, the inventors recognized
and appreciated that these characteristics permitted the use of
sequence tree data structures to efficiently compare sequence reads
and candidate clonotypes as compared with analytical approaches
using other data structures, e.g. lists, arrays, hash table, or the
like.
[0022] The enormous complexity of immune repertoires is well-known,
e.g. Arstila et al, Science, 286: 958-961 (1999) and Warren et al
(cited above). FIG. 1A illustrates diagrammatically a typical
transcript of an IgH molecule (120) from which a clonotype profile
is derived in accordance with some embodiments of the invention.
Sources of natural sequence variability include modular
recombination of the C, D, J and V segments from large sets carried
by the genome, nucleotide additions and deletions to the ends of
the D segment to produce the so-called "NDN" regions, and somatic
hypermutation where substitutions are made randomly over the length
of transcript (122) at a relative frequency roughly as indicated by
curve (128). In one aspect of the invention. complex populations of
such IgH and TCR transcripts are amplified and sequenced. In one
aspect one or both operations for IgH molecules are carried out by
using redundant primers annealing to different sites in the V
regions (described more fully below). This is particularly
advantageous where a sequencing chemistry is employed that has a
relatively high error rate or where such sequence variability is
difficult or impossible to know beforehand. In the latter case,
primer extension for amplification or generation of sequence reads
takes place even if one or more primer binding sites are
inoperable, or substantially inoperable, because of mismatches
caused (for example) by one or more somatic mutations. Starting
from promoter P (122) relative frequency shown by curve (128)
climbs through leader region (124) to a maximum over the V(D)J
region (126) of the transcript after which it drop to near zero. In
one aspect of the invention, a segment of recombined B cell nucleic
acid is amplified by a PCR with a plurality of forward primers or a
plurality of reverse primers to generate a nested set of templates
(see FIGS. 4A and 4B and their descriptions below). Templates from
such a set may be further amplified on a surface to form separate
amplicons (e.g. by bridge PCR using a cBot instrument; Illumina,
San Diego, Calif.). Templates from the same nested set may be
associated with one another by sequence reads generated at their
common ends. Nested sets of templates allow a sequencing chemistry
with relative high error rates to be used to analyze longer
sequences than otherwise would be possible, while at the same time
maintaining high average quality scores over the entire length of
the sequence. The nested sets also ensure that at least one
sequence read is obtained from a V region even if it has been
subjected to somatic hypermutation. In one embodiment, sequencing
chemistries may be used for analyzing highly variable nucleic
acids, such as IgH molecules, that have error rates no better than
the following: 0.2 percent of sequence reads contain at least one
error in positions 1-50; 0.2-1.0 percent of sequence reads contain
at least one error in positions 51-75; 0.5-1.5 percent of sequence
reads contain at least one error in positions 76-100; and 1-5
percent of sequence reads contain at least one error in positions
101-125. In view of the above, the method of the invention includes
steps for distinguishing clonotype sequences that are closely
related and genuinely different from those that are closely related
and the result of sequencing or other error.
[0023] Constructing clonotypes from sequence read data depends in
part on the sequencing method used to generate such data, as the
different methods have different expected read lengths and data
quality. In one approach, a Solexa sequencer is employed to
generate sequence read data for analysis. In one embodiment, a
sample is obtained that provides at least 0.5-1.0.times.10.sup.6
lymphocytes to produce at least 1 million template molecules, which
after optional amplification may produce a corresponding one
million or more clonal populations of template molecules (or
clusters). For most high throughput sequencing approaches,
including the Solexa approach, such over sampling at the cluster
level is, desirable so that each template sequence is determined
with a large degree of redundancy to increase the accuracy of
sequence determination. For Solexa-based implementations,
preferably the sequence of each independent template is determined
10 times or more. For other sequencing approaches with different
expected read lengths and data quality, different levels of
redundancy may be used for comparable accuracy of sequence
determination. Those of ordinary skill in the art recognize that
the above parameters, e.g. sample size, redundancy, and the like,
arc design choices related to particular applications.
[0024] Reducing a set of reads for a given sample to a set of
distinct clonotypes and recording the number of reads for each
clonotype would be a trivial computational problem if sequencing
technology was error free. However, in the presence of sequencing
errors, each genuine clonotype is surrounded by a `cloud` of reads
with, varying numbers of errors with respect to the its sequence.
The "cloud" of sequencing errors drops off in density as the
distance increases from the clonotype in sequence space. A variety
of algorithms are available for converting sequence reads into
clonotypes. In one aspect, coalescing of sequence reads (that is,
merging candidate clonotypes determined to have one or more
sequencing errors) depends on at least three factors: the number of
sequences obtained for each of the clonotypes being compared; the
number of bases at which they differ: and the sequencing quality
score at the positions at which they are discordant. A likelihood
ratio may be constructed and assessed that is based on the expected
error rates and binomial distribution of errors. For example, two
clonotypes, one with 150 reads and the other with 2 reads with one
difference between them in an area of poor sequencing quality will
likely be coalesced as they are likely to be generated by
sequencing error. On the other hand two clonotypes, one with 100
reads and the other with 50 reads with two differences between them
are not coalesced as they are considered to be unlikely to be
generated by sequencing error. In one embodiment of the invention,
the algorithm described below may be used for determining
clonotypes from sequence reads. Some of these concepts are
illustrated in FIG. 1B. In one aspect of the invention, sequence
reads are first converted into candidate clonotypes. Such a
conversion depends on the sequencing platform employed. For
platforms that generate high Q score long sequence reads, the
sequence read or a portion thereof may. be taken directly as a
candidate clonotype. For platforms that generate lower Q score
shorter sequence reads, some alignment and assembly steps may be
required for converting a set of related sequence reads into a
candidate clonotype. For example, for Solexa-based platforms, in
some embodiments, candidate clonotypes are generated from
collections of paired reads from multiple clusters, e.g. 10 or
more, as mentioned above. The frequencies of candidate clonotypes
may be plotted in sequence space, as illustrated in FIG. 1B, where
such space is reduced to one dimension (the horizontal axis) for
sake of illustration. The vertical axis gives the magnitude of each
candidate clonotype's frequency, log(read count), or some like
measure. In the figure, candidate clonotypes are represented by the
various symbols (130). In accordance with one embodiment of the
invention, whether two candidate clonotypes are coalesced depends
on their respective frequencies or read counts (as noted above),
the number of base differences between them (the more differences,
the less likely is coalescence), and the quality scores of the
bases at the locations where the respective sequences differ
(higher quality scores makes coalescence less likely). Candidate
clonotypes may be considered in the order of their respective
frequencies. FIG. 1B shows candidate clonotype 1 (132), candidate
clonotype 7 (134) and candidate clonotype 11 (136) as the three
candidates with the highest three frequencies. Related to each such
candidate clonotype are other candidate clonotypes that are close
in sequence, but with lesser frequencies, such as (i) for candidate
clonotype 1 (132) there are candidate clonotype 2 (138) and the
candidate clonotypes 3, 4, 5 and 6 enclosed by cone (140); for
candidate clonotype 7 (134) there arc candidate clonotypes 8, 9 and
10 enclosed by cone (142); and (iii) for candidate clonotype 11,
there is candidate clonotype 12 enclosed by cone (144). The cones
represent likelihood boundaries within which a lesser frequency
candidate clonotype would be coalesced with one of the higher
frequency candidate clonotypes 1, 7 or 11. Such likelihood
boundaries are functions of the frequency of the nearby candidate
clonotypes (3, 4, 5 and 6 for 1; 8, 9 and 10 for 7; and 12 for 11)
and their distances in sequence space from the respective higher
frequency candidate clonotypes. Candidate clonotype 2 (138) is
outside cone (140); thus, it would not be coalesced with candidate
clonotype 1 (132). Again, the likelihood (of coalesce) boundaries
are shown as cones because candidate clones with higher frequencies
are more likely to be genuinely different clonotypes than those of
lower frequencies and multiple differences at lower frequencies are
more likely to be errors than multiple differences at higher
frequencies.
[0025] The cloud of sequence reads surrounding each candidate
cloncotype can be modeled using the binomial distribution and a
simple, model for the probability of a single base error. This
latter error model can be inferred from mapping V and J segments or
from the clonotype finding algorithm itself, via self-consistency
and convergence. A model is constructed for the probability of a
given `cloud` sequence Y with read count C2 and E errors (with
respect to sequence X) being part of a true clonotype sequence X
with perfect read count C1 under the null model that X is the only
true clonotype in this region of sequence space. A decision is made
whether or not to coalesce sequence Y into the clonotype X
according the parameters C1, C2, and E. For any given C1 and E a
max value C2 is pre-calculated for deciding to coalesce the
sequence Y. The max values for C2 are chosen so that the
probability of failing to coalesce Y under the null hypothesis that
Y is part of clonotype X is less than some value P after
integrating over all possible sequences Y with error E in the
neighborhood of sequence X. The value P is controls the behavior of
the algorithm and makes the coalescing more or less permissive.
[0026] If a sequence Y is not coalesced into clonotype X because
its read count is above the threshold C2 for coalescing into
clonotype X then it, becomes a candidate for seeding separate
clonotypes (such as with candidate clonotype 2 (138) in FIG. 1B).
An algorithm implementing such principles would also make sure that
any other sequences Y2, Y3, etc. which are `nearer` to this
sequence Y (that had been deemed independent of X) are not
aggregated into X. This concept of `nearness` includes both error
counts with respect to Y and X and the absolute read count of X and
Y, i.e. it is modeled in the same fashion as the above model for
the cloud of error sequences around clonotype X. In this way
`cloud` sequences can be properly attributed to their correct
clonotype if they happen to be `near` more than one clonotype.
Thus, going to FIG. 1B, if candidate clonotype 2 is deemed to be
genuinely distinct from candidate clonotype 1 (132), then a special
routine, or subalgorithm, would provide a rule for determining
which of candidate clonotypes 1 (132) and 2 (138), candidates 4 and
5, between 1 and 2, should be coalesced to (if either).
[0027] In one embodiment, an algorithm proceeds in a top down
fashion by starting with the sequence X with the highest read
count. This sequence seeds the first clonotype. Neighboring
sequences are either coalesced into this clonotype if their counts
are below the precalculated thresholds (see above), or left alone
if they are above the threshold or `closer` to another sequence
that was not coalesced. After searching all neighboring sequences
within a maximum error count, the process of coalescing reads into
clonotype X is finished. Its reads and all reads that have been
coalesced into it are accounted for and removed from the list of
reads available for making other clonotypes. The next sequence is
then moved on to with the highest read count. Neighboring reads are
coalesced into this clonotype as above and this process is
continued until there are no more sequences with read counts above
a given threshold, e.g. until all sequences with more than 1 count
have been used as seeds for clonotypes.
[0028] As mentioned above, in another embodiment of the above
algorithm, a further test may be added for determining whether to
coalesce a candidate sequence Y into an existing clonotype X, which
takes into account quality score of the relevant sequence reads.
The average quality store(s) are determined for sequence(s) Y
(averaged across all reads with sequence Y) were sequences Y and X
differ. If the average score is above a predetermined value then it
is more likely that the difference indicates a truly different
clonotype that should not be coalesced and if the average score is
below such predetermined value then it is more likely that sequence
Y is caused by sequencing errors and therefore should be coalesced
into X.
[0029] Successful implementation of the above algorithm for
coalescing candidate clonotypes is dependent upon having an
efficient way of finding all sequences with less than E errors
(i.e. less than some sequence distance measure) from some input
sequence X. This problem is solved using a sequence tree. The
implementation of such trees has sonic unusual features in that the
nodes of the tree are not restricted to being single letters of the
DNA sequences of the candidate clonotypes, as illustrated in FIG.
1E. The nodes can have arbitrarily long sequences, which allows for
a more efficient use of computer memory.
[0030] All of the reads of a given sample are placed into the
sequence tree. Each leaf nodes holds pointers to its associated
reads. A unique sequence of a candidate clonotype is retrieved by
traversing backwards in the tree from the leaf to the root node.
The first sequence is placed into a simple tree with one root node
and one leaf node that contains the full sequence of the read.
Sequences arc next added one by one. For each added sequence either
a new branch is formed at the last point of common sequence between
the read and the existing tree or add the read to an existing leaf
node if the tree already contains the sequence. Having placed all
the reads into the tree it is easy to use the tree for the
following purposes: 1) Finding the highest read count: sorting leaf
nodes by read count allows one to find the leaf node (i.e.
sequence) with the most reads, and successively lower numbers of
reads; 2) Finding neighboring leafs: for any sequence all paths
through the tree which have less than X errors with respect to this
sequence are searchable. A path is started at the root and branch
this path into separate paths proceeding along the tree. The
current error count of each path as proceeding along the tree is
noted. When the error count exceeds the max allowed errors the
given path is terminated. In this way large parts of the tree arc
pruned as early as possible. This is an efficient way of finding
all paths.(i.e. all leafs) within X errors from any given
sequence.
[0031] Features of the above concepts are illustrated in more
detail in the flow chart of FIG. 1C. A set of candidate clonotypes
is obtained from sequence data obtained by sequencing recombined
nucleic acids extracted from a sample of T cells or B cells. In one
aspect, candidate clonotypes each include an NDN region and
portions of V and J regions. These sequences are organized into a
data structure (150), which may be a sequence tree. Not shown in
FIG. 1C, as part of generating a set of candidate clonotypes, in
one embodiment, sequence trees may also be constructed for known V
regions and known J regions. Sequence reacts making up a candidate
clonotype may then be mapped, or aligned, to these known sequences
via the sequence trees to, efficiently determine the most likely
known V and J sequences of the candidate clonotypes. Returning to
FIG. 1C, once the candidate clonotypes are generated, a data
structure, such as a sequence tree, is constructed for uses in a
method for distinguishing genuine clonotypes from candidate
clonotypes that contain experimental or measurement errors, such as
sequencing errors. The candidate clonotype that has the highest
frequency of occurrence among the current candidate clonotypes
(HFCC.sub.k) is selected (152) from the data structure, for example
a sequence tree; in other words, HFCC.sub.k is the candidate
clonotype with the highest number of copies, or read counts in
cycle k. Next, neighboring lesser frequency candidate clonotypes
arc identified (LFCCs) (154); that is, candidate clonotypes within
a distance of D.sub.k arc identified. In one aspect of the
invention, this identification is carried out using a sequence
tree, which allows efficient sequence comparisons of relatively
short (<300 bp) sequences. In one embodiment, the comparisons,
or sequence alignments, are carried out using dynamic programming,
e.g. as disclosed by Gusfield (cited above). In a further
embodiment, such dynamic programming is banded dynamic programming
where sequences that differ from the selected HFCC by more than a
predetermined distance are not considered, which speeds the
computation. The candidates HFCC.sub.k and LFCC.sub.j may be
compared on the basis of many different criteria or properties. In
one aspect, as mentioned above, candidate clonotypes arc compared
on the basis of at least two properties: (i) frequency or read
counts and (ii) sequence differences. In another aspect, as
mentioned above, candidate clonotypes are compared on the basis of
at least three properties: (i) frequency or read counts, (ii)
sequence differences, and (iii) quality scores or measures of the
bases where differences occur. In one embodiment, sequence
differences include base substitutions; in another embodiment,
sequence differences include base substitutions, deletions and
insertions. The latter embodiment is especially applicable whenever
sequence data is generated by sequencing-by-synthesis chemistries
that do not employ terminators, such as 454 sequencers and Ion
Torrent sequencers. Such sequencing approaches differentiate
different sized homopolymer stretches by signal amplitude; thus,
base-calling routines in such approaches are prone to insertion and
deletion errors, because the difference in signal level from
homopolymers differing by one nucleotide drops percipitiousty with
increasing homopolymer size (that is, a 2-mer is readily
distinguished from a 3-mer, but an 8-mer is almost
indistinguishable from a 9-mer). In one aspect, comparisons of
HFCCs and LFCCs may be implemented using a function, such as
P(HFCC.sub.k, LFCC.sub.j, D, Q) shown in decision box (158), which
depends on the quantities (i) through (iii) described above. Such a
function may take many different forms, but generally the value of
P changes with changes in (i), (ii) and (iii) as follows: The value
of P preferably increases monotonically with the frequency of HFCC
and the ratio of the frequency of HFCC to that of LFCC, such that
the higher the ratio of the frequency of HFCC to that of LFCC, the
higher the likelihood LFCC will be coalesced into HFCC. Likewise,
the value of P preferably decreases monotonically with degree to
which the sequences of HFCC and LFCC differ, so that the greater
the difference between HFCC and LFCC (e.g. as measured by the
minimal number of substitutions, insertions or deletions to change
one to the other) the lower the likelihood LFCC will be coalesced
with HFCC. Finally, the value of P preferably decreases
monotonically with increasing quality scores of the locations where
the sequences of HFCC and LFCC differ, so that for higher quality
scores, the lower the likelihood LFCC will be coalesced with HFCC.
When the sequences of HFCC and LFCC differ at more than one
location, the quality scores at the different locations may be
combined in a variety of differ ways. In one embodiment, whenever
there is a plurality of such differences, the plurality of quality
scores is expressed as an average value, which may be either an
unweighted average or a weighted average. FIG. 1D shows an
exemplary function, P, computed for different quality values
(curves a through e) for a given sequence difference. As
illustrated in FIG. 1D, whenever HFCC is at a level of about 200
read counts (170), then if the quality scores arc determined by
curve (a), any LFCC with less than about 50 read counts (172) are
coalesced into HFCC. The argument, D, of function P is a measure of
the distance between the sequences HFCC.sub.k and LFCC; and its
value may vary from cycle to cycle as an analysis progresses. (The
indices "k" indicates that the values of constants with a "k"
subscript may depend on the computational cycle, k.) In one
embodiment, D=D.sub.k, so that its value is a function of cycle,
number. In another embodiment, D=D(HFCC frequency), so that its
value is a function of the frequency of HFCC; independent of cycle
number. For example, as the frequency of HFCC decreases, then
distance, D, of candidates to be compared decreases. In one
embodiment, D is a Hamming distance between HFCC.sub.k and
LFCC.sub.j; however, other distance measures may be used. In one
embodiment, D.sub.k is a non-increasing function of k: and in
another embodiment, D.sub.k is a decreasing function of k.
Decreasing the magnitude of D with increasing cycle number, or with
decreasing frequency of HFCC, is advantageous in some embodiments
because as a computation progresses to lower and lower frequency
candidate clonotypes most such candidates arc singletons, so that
sequence distance (rather than frequency difference) becomes the
predominant comparison. By lowering D as the computation
progresses, unproductive comparisons to distant low frequency
candidate clonotypes are reduced, thereby speeding up the
computation. Function P may be a complicated expression depending
on the number of factors being considered. FIG. 1D illustrates
computed values for one embodiment of P which relates read count
thresholds for coalescing an LFCC given a read count of an HFCC for
different quality scores, as described above. Curves "a" through
"c" represent the relationships for different quality scores (with
curve "a" corresponding to the highest quality score).
[0032] Returning to FIG. 1C, if P<P.sub.k, then LFCC; is not
coalesced with HFCC.sub.k and another LFCC is selected (160). If
P>P.sub.k, then LFCC; is coalesced with HFCC.sub.k (162), in
which case another LFCC is selected (166), unless there are no more
LFCC left to evaluate (164). If there, are no more LFCC to evaluate
(164), then the current HFCC.sub.k (including all of the LFCC's
coalesced into it) is removed (168) from the data structure, such
as the sequence tree. Such removal is illustrated in the simple
sequence tree (190) of FIGS. 1E-F. There, path (192) (indicated by
dashed line) in sequence tree (190) corresponds to HFCC (196),
which is coalesced with LFCC (198). After coalescence, the segment
of path (192) in shaded area (199) is removed from sequence tree
(190)to give reduced sequence tree (197) shown in FIG. 1F, which is
used in subsequent computations to find neighboring LFCC (154).
After such removal, clonotype determination is finished if a
stopping criterion (170) is met. In one embodiment, stopping
criterion (170) is whether the last non-singleton candidate
clonotype has been processed (152). In another embodiment, stopping
criterion (170) is whether the frequency or the read counts of the
selected HFCC is below that corresponding to a single lymphocyte.
In one aspect of the method of the invention, an amplification step
may result in each lymphocyte in a sample being represented by
multiple copies of the same clonotype; thus, in one embodiment,
whatever HFCC has a number of read counts below the number
corresponding to a single lymphocyte, then the computation is
stopped. In some embodiments, such a number of read counts (or
candidate clonotype copies) is 10; in another embodiment, such
number is 20; in another embodiment, such a number is 30; in
another embodiment, such a number is 40. If the stopping criterion
is not met, then the next HFCC is selected (172). The analytical
steps summarized in the flow chart of FIG. 1C may be implemented in
any suitable programming language, such as C, C++. Java, C#,
Fortran, Pascal or the like.
[0033] In accordance with one aspect of the invention; the above
method for determining clonotypes and/or clonotype profiles
comprises steps of (a) forming a data structure of recombined
immune molecules from sequence reads obtained by high throughput
nucleic acid sequencing, (b) coalescing with a highest frequency
candidate clonotype any lesser frequency candidate clonotypes
whenever such lesser frequency is below a predetermined frequency
value and a sequence difference therebetween is below a
predetermined difference value to form a clonotype, (c) removing
the coalesced candidate clonotype from the data structure, and (d)
repeatine, steps (b) and (c) until a clonotype profile is formed.
In one embodiment, the data structure is a sequence tree.
[0034] In accordance with another aspect of the invention, the
above method of determining clonotypes may be carried out by steps
comprising: (a) providing a set of sequence reads from a repertoire
of recombined immune molecules each having a V region, an NDN
region and a J region wherein for each such molecule at least one
sequence read encompasses at least a portion of the NDN region of
such molecule; (b) forming from sequence reads encompassing at
least a portion of an NDN region a sequence tree having leaves
representing candidate clonotypes, each leaf and its corresponding
candidate clonotype having a frequency; (c) coalescing with a
highest frequency candidate clonotype any lesser frequency
candidate clonotypes whenever such lesser frequency is below a
predetermined frequency value and a sequence difference
therebetween is below a predetermined difference value to form a
clonotype having a sequence of the highest frequency candidate
clonotype; (d) removing leaves corresponding to the coalesced
candidate clonotypes from the sequence tree; and (e) repeating
steps (c) and (d) until a highest frequency of a lesser frequency
candidate clonotype is below a predetermined stopping value. In one
embodiment, the step of forming further includes selecting a
highest frequency candidate clonotype and identifying all said
lesser frequency candidate clonotypes having a sequence difference
therewith less than a predetermined difference value to form a
coalescence subset. Thus, in such embodiment, one may limit the
total number of LFCCs that must be compared for the coalescing
operation (only ones within the predetermined difference value are
considered). Such value is a process input depending on the
application, e.g. the size of the repertoire, how much computing
time is used, and so on. As mentioned above, the function used for
deciding whether to coalesce an HFCC with a LFCC can have a variety
of forms. In one general aspect, for the step of coalescing, such a
function may have the following properties. It depends on
frequencies of HFCC, LFCC, the sequence difference therebetween
(which may be expressed as a conventional string difference
measure, such as a Hamming distance) and quality scores of the one
or more nucleotide locations where the HFCC and LFCC differ; such
that the function (i) monotonically increases with increasing ratio
of frequency of HFCC and frequency of LFCC, (ii) monotonically
decreases with increasing sequence difference between HFCC and
LFCC, and (iii) monotonically decreases with increasing quality
scores of the one or more nucleotide locations. That is, in regard
to property (iii), the surer one is that HFCC and LFCC are
different (e.g., because there is a high level of confidence in the
base calls), then the less likely they will be coalescenced.
[0035] In the foregoing, selection of a predetermined frequency
value and a predetermined difference value is a design choice that
depend on particular applications. Factors affecting such choices
may include details of the biology, speed of implementation, and
the like.
Samples
[0036] Complex populations of nucleic acids for analysis may arise
from a variety of sources. Immune system repertoires may be
obtained from samples of immune cells. For example, immune cells
can include T-cells and/or B-cells. T-cells (T lymphocytes)
include, for example, cells that express T cell receptors. T-cells
include helper T cells (effector T cells or Th cells), cytotoxic T
cells (CTLs), memory T cells, and regulatory T cells. In one aspect
a sample of T cells includes at least 1,000T cells; but more
typically, a sample includes at least 10,000 T cells, and more
typically, at least 100;000 T cells. In another aspect, a sample
includes a number of T cells. In the range of from 1000 to
1,000,000 cells. A sample of immune cells may also comprise B
cells. B-cells include, for example, plasma B cells, memory B
cells, B1 cells, B2 cells, marginal-zone B cells, and follicular B
cells. B-cells can express immunoglobulins (antibodies, B cell
receptor). As above, in one aspect a sample of B cells includes at
least 1,000 B cells; but more typically, a sample includes at least
10,009 B cells, and more typically, at least 100,000 B cells. In
another aspect, a sample includes a number of Bcells in the range
of from 1000 to 1,000,000 B cells.
[0037] The sample can include nucleic acid, for example, DNA (e.g.,
genomic DNA or thitocliondrial DNA) or RNA (e.g., messenger RNA or
microRNA). The nucleic acid can be cell-free DNA or RNA, e.g.
extracted from the circulatory system, Vlassov et al, Curr. Mol.
Med., 10: 142-165 (2010); Swamp et al, FEBS Lett., 581: 795-799
(2007). In the methods of the provided invention, the amount of RNA
or DNA from a subject that can be analyzed includes, for example,
as low as a single cell in some applications (e.g., a calibration
test) and as many as 10 million of cells or more translating to a
range of DNA of 6 pg-60 ug, and RNA of approximately 1 pg-10
ug.
[0038] As discussed more fully below (Definitions), a sample of
lymphocytes is sufficiently large so that substantially every T
cell or B cell with a distinct clonotype is represented therein,
thereby forming a repertoire (as the term is used herein). In one
embodiment, a sample is taken that contains with a probability of
ninety-nine percent every clonotype of a population present at a
frequency of 0.001 percent or greater. In another embodiment, a
sample is taken that contains with a probability of ninety-nine
percent every clonotype of a population present at a frequency of
0.0001 percent or greater. In one embodiment, a sample of B cells
or T cells includes at least a half million cells, and in another
embodiment such sample includes at least one million cells.
[0039] Whenever a source of material from which a sample is taken
is scarce, such as, clinical study samples, or the like, DNA from
the material may be amplified by a non-biasing technique, such as
whole genome amplification (WGA), multiple displacement
amplification (MDA); or like technique, e.g. Hawkins et al, Curr.
Opin. Biotech., 13: 65-67 (2002); Dean et al, Genome Research, 11:
1095-1099 (2001); Wang et al, Nucleic. Acids Research, 32: e76
(2004); Hosono ct al, Genome Research, 13: 954-964 (2003); and the
like.
[0040] 100401 Blood samples are of particular interest, especially
in monitoring lymphoid neoplasms, such as lymphomas, leukemias, or
the like; and may be obtained using conventional techniques, e.g.
Innis et al, editors, PCR Protocols (Academic Press, 1990); or the
like. For example, white blood cells may be separated from blood
samples using convention techniques, e.g. RosetteSep kit (Stem Cell
Technologies, Vancouver, Canada). Blood samples may range in volume
from 100 .mu.L to 10 mL; in one aspect, blood sample volumes are in
the range of from 200 100 .mu.L to 2 mL. DNA and/or RNA may then be
extracted from such blood sample using conventional techniques for
use in methods of the invention, e.g. DNeasy Blood & Tissue Kit
(Qiagen, Valencia, Calif.). Optionally, subsets of white blood
cells, e.g. lymphocytes, may be further isolated using conventional
techniques, e.g. fluorescently activated cell sorting (FACS)
(Becton Dickinson, San Jose, Calif.), magnetically activated cell
sorting (MACS) (Miltenyi Biotec, Auburn, Calif.), or the like.
[0041] Since the identifying recombinations are present in the DNA
of each individual's adaptive immunity cell as well as their
associated RNA transcripts, either RNA or DNA can be sequenced in
the methods of the provided invention. A recombined sequence from a
T-cell or B-cell encoding a T cell receptor or immunoglobulin
molecule, or a portion thereof, is referred to as a clonotype. The
DNA or RNA can correspond to sequences from T-cell receptor (TCR)
genes or immunoglobulin (Ig) genes that encode antibodies. For
example, the DNA and RNA can correspond to sequences encoding
.alpha., .beta., .gamma., or .delta. chains of a TCR. In a majority
of T-cells, the TCR is a heterodimer consisting of an .alpha.-chain
and .beta.-chain. The TCR.alpha. chain is generated by VJ
recombination, and the .beta. chain receptor is generated by V(D)J
recombination. For the TCR.beta. chain, in humans there arc 48 V
segments, 2 D segments, and 13 J segments. Several bases may be
deleted and others added (called N and P nucleotides) at each of
the two junctions. In a minority of T-cells, the TCRs consist of
.gamma. and .delta. delta chains. The TCR .gamma. chain is
generated by VJ recombination, and the TCR .delta. chain is
generated by V(D)J recombination (Kenneth Murphy, Paul Travers, and
Mark Walport, Janeway's Immunology 7th edition, Garland Science,
2007, which is herein incorporated by reference in its
entirety).
[0042] The DNA and RNA analyzed in the methods of the invention can
correspond to sequences encoding heavy chain immunoglobulins ago
with constant regions (.alpha., .delta., .epsilon., .gamma., or
.mu.) or light chain immunoglobulins (IgK or IgL) with constant
regions .lamda. or .kappa.. Each antibody has two identical light
chains and two identical heavy chains. Each chain is composed of a
constant (C) and a variable region. For the heavy chain, the
variable region is composed of a variable (V), diversity (D), and
joining (J) segments. Several distinct sequences coding for each
type of these segments are present in the genome. A specific VDJ
recombination event occurs during the development of a B-cell,
marking that cell to generate a specific heavy chain. Diversity in
the light chain is generated in a similar fashion except that there
is no D region so there is only VJ recombination. Somatic mutation
often occurs close to the site of the recombination, causing the
addition or deletion of several nucleotides, further increasing the
diversity of heavy and light chains generated by B-cells. The
possible diversity of the antibodies generated by a B-cell is then
the product of the different heavy and light chains. The variable
regions of the heavy and light chains contribute to form the
antigen recognition (or binding) region or site. Added to this
diversity is a process of somatic hypermutation which can occur
after a specific response is mounted against some epitope.
[0043] As mentioned above, in accordance with the invention,
primers may be selected to generate amplicons of subsets of
recombined nucleic acids extracted from lymphocytes. Such subsets
may be referred to herein as "somatically rearranged regions."
Somatically rearranged regions may comprise nucleic acids from
developing or from fully developed lymphocytes, where developing
lymphocytes are cells in which rearrangement of immune genes has
not been completed to form molecules having full V(D)J regions.
Exemplary incomplete somatically rearranged regions include
incomplete IgH molecules (such as, molecules containing only D-J
regions), incomplete TCR.delta. molecules (such as, molecules
containing only D-J regions), and inactive IgK (for example,
comprising Kdc-V regions).
[0044] Adequate sampling of the cells is an important aspect of
interpreting the repertoire data, as described further below in the
definitions of "clonotype" and "repertoire" For example, starting
with 1,000 cells creates a minimum frequency that the assay is
sensitive to regardless of how many sequencing reads are obtained.
Therefore one aspect of this invention is the development of
methods to quantitate the number of input immune receptor
molecules. This has been implemented this for TCR.beta. and IgH
sequences. In either case the same set of primers are used that are
capable of amplifying all the different sequences. In order to
obtain an absolute number of copies, a real time PCR with the
multiplex of primers is performed along with a standard with a
known number of immune receptor copies. This real time PCR
measurement can be made from the amplification reaction that will
subsequently be sequenced or can be done on a separate aliquot of
the same sample. In the case of DNA, the absolute number of
rearranged immune receptor molecules can be readily converted to
number of cells (within 2 fold as some cells will have 2 rearranged
copies of the specific immune receptor assessed and others will
have one). In the case of cDNA the measured total number of
rearranged molecules in the real time sample can be extrapolated to
define the total number of these molecules used in another
amplification reaction of the same sample. In addition, this method
can be combined with a method to determine the total amount of RNA
to define the number of rearranged immune receptor molecules in a
unit amount (say 1 .mu.g) of RNA assuming a specific efficiency of
cDNA synthesis. If the total amount of cDNA is measured then the
efficiency of cDNA synthesis need not be considered. If the number
of cells is also known then the rearranged immune receptor copies
per cell can be computed. If the number of cells is not known, one
can estimate it from the total RNA as cells of specific type
usually generate comparable amount of RNA. Therefore from the
copies of rearranged immune receptor molecules per 1.mu.g one can
estimate the number of these molecules per cell.
[0045] One disadvantage of doing a separate real time PCR from the
reaction that would be processed for sequencing is that there might
be inhibitory effects that are different in the real time PCR from
the other reaction as different enzymes, input DNA, and other
conditions may be utilized. Processing the products of the real
time PCR for sequencing would ameliorate this problem. However low
copy number using real time PCR can be die to either low number of
copies or to inhibitory effects, or other suboptimal conditions in
the reaction.
[0046] Another approach that can be utilized is to add it known
amount of unique immune receptor rearranged molecules with a known
sequence, i.e. known amounts of one or more internal standards, to
the cDNA or gnomic DNA from a sample of unknown quantity. By
counting the relative number of molecules that are obtained for the
known added sequence compared to the rest of the sequences of the
same sample, one can estimate the number of rearranged immune
receptor molecules in the initial cDNA sample. (Such techniques for
molecular counting arc well-known, e.g. Brenner et al, U.S. Pat.
No. 7,537,897, which is incorporated herein by reference). Data
from sequencing the added unique sequence can be used to
distinguish the different possibilities if a real time PCR
calibration is being used as well. Low copy number of rearranged
immune receptor in the DNA (or cDNA) would create a high ratio
between the number of molecules for the spiked sequence compared to
the rest of the sample sequences. On the other hand, if the
measured low copy number by real time PCR is due to inefficiency in
the reaction, the ratio would not be high.
Amplification of Nucleic Acid Populations
[0047] As noted below, amplicons of target populations of nucleic
acids may be generated by a variety of amplification techniques. In
one aspect of the invention, multiplex PCR is used to amplify
members of a mixture of nucleic acids, particularly mixtures
comprising recombined immune molecules such as T cell receptors, B
cell receptors, or portions thereof. Guidance for carrying out
multiplex PCRs of such immune molecules is found in the following
references, which are incorporated by reference: Morley, U.S. Pat.
No. 5,296,351; Gorski, U.S. Pat. No. 5,837,447; Dau, U.S. Pat. No.
6,087,096; Von Dongen et al, U.S. patent publication 2006/0234234;
European patent publication EP 1544308B1; and the like. The
foregoing references describe the technique referred to as
"spectratyping," where a population of immune molecules are
amplified by multiplex PCR after which the sequences of the
resulting amplicon are physically separated, e.g. by
electrophoresis, in order to determine whether there is a
predominant size class. Such a class would indicate a predominant
clonal population of lymphocytes-which, in turn, would be
indicative of disease state. In spectratyping, it is important to
select primers that display little or no cross-reactivity (i.e.
that do not anneal to binding sites of other primers); otherwise
there may be a false representation of size classes in the
amplicon. In the present invention, so long as the nucleic acids of
a population are uniformly amplified, cross-reactivity of primers
is permissible because the sequences of the amplified nucleic acids
are analyzed in the present invention, not merely their sizes. As
described more fully below, in one aspect, the step of spatially
isolating individual nucleic acid molecules is achieved by carrying
out a primary multiplex amplification of a preselected somatically
rearranged region or portion thereof (i.e. target sequences) using
forward and reverse primers that each have tails non-complementary
to the target sequences to produce a first amplicon whose member
sequences have common sequences at each end that allow further
manipulation. For example, such common ends may include primer
binding sites for continued amplification using just a single
forward primer and a single reverse primer instead of multiples of
each, or for bridge amplification of individual molecules on a
solid surface, or the like. Such common ends may be added in a
single amplification as described above, or they may be added in a
two-step procedure to avoid difficulties associated with
manufacturing and exercising quality control over mixtures of long
primers (e.g. 50-70 bases or more). In such a two-step process
(described more fully below and illustrated in FIGS. 4A-4B), the
primary amplification is carried out as described above, except
that the primer tails are limited in length to provide only forward
and reverse primer binding sites at the ends of the sequences of
the first amplicon. A secondary amplification is then carried out
using secondary amplification primers specific to these primer
binding sites to add further sequences to the ends of a second
amplicon. The secondary amplification primers have tails
non-complementary to the target sequences, which form the ends of
the second amplicon and which may, be used in connection With
sequencing the clonotypes of the second amplicon. In one
embodiment, such added sequences may include primer binding sites
for generating sequence reads and primer binding sites for carrying
out bridge PCR on a solid surface to generate clonal populations of
spatially isolated individual molecules, for example, when
Solexa-based sequencing is used. In this latter approach, a sample
of sequences from the second amplicon are disposed on a solid
surface that has attached complementary oligonucleotides capable of
annealing to sequences of the sample, idler which cycles of primer
extension, denaturation, annealing are implemented until clonal
populations of templates are formed. Preferably, the size of the
sample is selected so that (i) it includes an effective
representation of clonotypes in the original sample, and (ii) the
density of clonal populations on the solid surface is in a range
that permits unambiguous sequence determination of clonotypes.
[0048] TCR or BCR sequences or portions thereof can be amplified
from nucleic acid in a multiplex reaction using at least one primer
that anneals to the C region and one or more primers that can
anneal to one or more V segments (as illustrated in FIGS. 2A-2B and
FIGS. 4A-4B and discussed more fully below). The region to be
amplified can include the full clonal sequence or a subset of the
clonal sequence, including the V-D junction, D-J junction of an
inummoglobulin or T-cell receptor gene, the full variable region of
an immunoglobulin or T-cell receptor gene, the antigen recognition
region, or a CDR, e.g., complementarity determining region 3
(CDR3).
[0049] The TCR or immunoglobulin sequence can amplified using a
primary and a secondary amplification step. Each of the different
amplification steps can comprise different primers. The different
primers can introduce sequence not originally present in the immune
gene sequence. For example, the amplification procedure can add new
primer binding sites to the ends of the target sequences to convert
a multiplex amplification to a singleplex amplification or the
amplification procedure can add one or more tags to the 5' and/or
3' end of amplified TCR or immunoglobulin sequence (as illustrated
in FIGS. 3A-3B). The tag can be sequence that facilitates
subsequent sequencing of the amplified DNA. The tag can be sequence
that facilitates binding the amplified sequence to a solid
support.
[0050] After amplification of DNA from the genome (or amplification
of nucleic acid in the form of cDNA by reverse transcribing RNA),
the individual nucleic acid molecules can be isolated, optionally
re-amplified, and then sequenced individually. Exemplary
amplification protocols may be found in van Dongen et al, Leukemia,
17: 2257-2317 (2003) or van Dongen et al, U.S. patent publication
2006/0234234, which is incorporated by reference. Briefly, an
exemplary protocol is as follows: Reaction buffer: ABI Buffer II or
ABI Gold Buffer (Life Technologies, San Diego, Calif.); 50 .mu.L
final reaction volume; 100 ng sample DNA; 10 pmol of each primer
(subject to adjustments to balance amplification as described
below); dNTPs at 200 .mu.M final concentration; MgCl.sub.2 at 1.5
mM final concentration (subject to optimization depending on target
sequences and polymerase); Taq polymerase (1-2 U/tube); cycling
conditions: preactivation 7 min at 95.degree. C.; annealing at
60.degree. C.; cycling times: 30 s denaturation; 30 s annealing; 30
s extension. Polymerases that can be used for amplification in the
methods of the invention are commercially available and include,
for example, Taq polymerase, AccuPrime polymerase, or Pfu. The
choice of polymerase to use can be based on whether fidelity or
efficiency is preferred.
[0051] Methods for isolation of nucleic acids from a pool include
subcloning nucleic acid into DNA vectors and transforming bacteria
(bacterial cloning), spatial separation of the molecules in two
dimensions on a solid substrate (e.g., glass slide), spatial
separation of the molecules in three dimensions in a solution
within micelles (such as can be achieved using oil emulsions with
or without immobilizing the molecules on a solid surface such as
beads), or using microreaction chambers in, for example,
microfluidic or nano-fluidic chips. Dilution can be used to ensure
that on average a single molecule is present in a given volume,
spatial region, bead, or reaction chamber. Guidance for such
methods of isolating individual nucleic acid molecules is found in
the following references: Sambrook, Molecular Cloning: A Laboratory
Manual (Cold Spring Harbor Laboratory Press, 2001s); Shendure et
at, Science, 309: 1728-1732 (including supplemental matcrial)
(2005); U.S. Pat. No. 6,300,070; Bentley ct al, Nature, 456:53-59
(including supplemental material) (2008); U.S. Pat. No. 7,323,305;
Matsubara ct al, Biosensors & Bioelectronics, 20: 1482-1490
(2005): U.S. Pat. No. 6,753,147; and the like.
[0052] Real time PCR, picogreen staining, nanofluidic
electrophoresis (e.g. LabChip) or UV absorption measurements can be
used in an initial step to judge the functional amount of
amplifiable material.
[0053] In one aspect, multiplex amplifications are carried out so
that relative amounts of sequences in a starting population arc
substantially the same as those in the amplified population, or
amplicon. That is, multiplex amplifications are carried out with
minimal amplification bias among member sequences of a sample
population. In one embodiment, such relative amounts are
substantially the same if each relative amount in an amplicon is
within five fold of its value in the starting sample. In another
embodiment, such relative amounts are substantially the same if
each relative amount in an amplicon is within two fold of its value
in the starting sample. As discussed more fully below,
amplification bias in PCR may be detected and corrected using
conventional techniques so that a set of PCR primers may be
selected for a predetermined repertoire that provide unbiased
amplification of any sample.
[0054] In regard to many repertoires based on TCR or BCR sequences,
a multiplex amplification optionally uses all the V segments. The
reaction is optimized to attempt to get amplification that
maintains the relative abundance of the sequences amplified by
different V segment primers. Some of the primers are related, and
hence many of the primers may "cross talk," amplifying templates
that arc not perfectly matched with it. The conditions arc
optimized so that each template can be amplified in a similar
fashion irrespective of which primers amplified it. In other words
if there are two templates, then after 1,000 fold amplification
both templates can be amplified approximately 1,000 fold, and it
does not matter that for one of the templates half of the amplified
products carried a different primer because of the cross talk. In
subsequent analysis of the sequencing data the primer sequence is
eliminated from the analysis, and hence it does not matter what
primer is used in the amplification as long as the templates are
amplified equally.
[0055] In one embodiment, amplification bias may be avoided by
carrying out a two-stage amplification (as illustrated in FIGS.
2A-2B) wherein a small number of amplification cycles are
implemented in a first, or primary, stage using primers having
tails non-complementary with the target sequences. The tails
include primer binding sites that arc added to the ends of the
sequences of the primary amplicon so that such sites arc used in a
second stage amplification using only a single forward primer and a
single reverse primer, thereby eliminating a primary cause of
amplification bias. Preferably, the primary PCR will have a small
enough number of cycles (e.g. 5-10) to minimize the differential
amplification by the different primers. The secondary amplification
is done with one pair of primers and hence the issue of
differential amplification is minimal. One percent of the primary
PCR is taken directly to the secondary PCR. Thirty-five cycles
(equivalent to 28 cycles without the 100 fold dilution step) used
between the two amplifications were sufficient to show a robust
amplification irrespective of whether the breakdown of cycles were:
one cycle primary and 34 secondary or 25 primary and 10 secondary.
Even though ideally doing only 1 cycle in the primary PCR may
decrease the amplification bias, there arc other considerations.
One aspect of this is representation. This plays a role when the
stalling input amount is not in excess to the number of reads
ultimately obtained. For example, if 1,000,000 reads are obtained
and starting with 1,000,000 input Molecules then taking only
representation from 100,000 molecules to the secondary
amplification would degrade the precision of estimating the
relative abundance of the different species in the original sample.
The 100 fold dilution between the 2 steps means that the
representation is reduced unless the primary PCR amplification
generated significantly more than 100 molecules. This indicates
that a minimum 8 cycles (256 fold), but more comfortably 10 cycle
(1,000 fold), may be used. The alternative to that is to take more
than 1% of the primary PCR into the secondary but because of the
high concentration of primer used in the primary PCR, a big
dilution factor is can be used to ensure these primers do not
interfere in the amplification and worsen the amplification bias
between sequences. Another alternative is to add a purification or
enzymatic step to eliminate the primers from the primary PCR to
allow a smaller dilution of it. In this example, the primary PCR
was 10 cycles and the second 25 cycles.
Generating Sequence Reads for Clonotypes
[0056] Any high-throughput technique for sequencing nucleic acids
can be used in the method of the invention. Preferably, such
technique has a capability of generating in a cost-effective manner
a volume of sequence data from which at least 1000 clonotypes can
be determined, and preferably, from which at least 10,000 to
1,000,000 clonotypes can be determined. DNA sequencing techniques
include classic dideoxy sequencing reactions (Sanger method) using
labeled terminators or primers and gel separation in slab or
capillary, sequencing by synthesis using reversibly terminated
labeled nucleotides, pyrosequencing, 454 sequencing, allele
specific hybridization to a library of labeled oligonucleotide
probes, sequencing by synthesis using allele specific hybridization
to a library of labeled clones that is followed by ligation, real
time monitoring of the incorporation of labeled nucleotides during
a polymerization step, polony sequencing, and SOLiD sequencing.
Sequencing of the separated molecules has more recently been
demonstrated by sequential or single extension reactions using
polymerases or ligases as well as by single or sequential
differential hybridizations with libraries of probes. These
reactions have been performed on many clonal sequences in parallel
including demonstrations in current commercial applications of over
100 million sequences in parallel. These sequencing approaches can
thus be used to study the repertoire of T-cell receptor (TCR)
and/or B-cell receptor (BCR). In one aspect of the invention,
high-throughput methods of sequencing are employed that comprise a
step of spatially isolating individual molecules on a solid surface
where they are sequenced in parallel. Such solid surfaces may
include nonporous surfaces (such as in Solexa sequencing, e.g.
Bentley et al, Nature, 456: 53-59 (2008) or Complete Genomics
sequencing, e.g. Drmanac et al, Science, 327: 78-81 (2010)), arrays
of wells, which may include bead- or particle-bound templates (such
as with 454, e.g. Margulies et al, Nature, 437: 376-380 (2005) or
Ion Torrent sequencing, U.S. patent publication 2010/0137143 or
2010/0304982), micromachined membranes (such as with SMRT
sequencing, e.g. Eid et al, Science, 323: 133-138 (2009)), or bead
arrays (as with SOLiD sequencing or polony sequencing, e.g. Kim et
al, Science, 316: 1481-1414 (2007)). In another aspect, such
methods comprise amplifying the isolated molecules either before or
after they arc spatially isolated on a solid surface. Prior
amplification may comprise emulsion-based amplification, such as
emulsion PCR, or rolling circle amplification. Of particular
interest is Solexa-based sequencing where individual template
molecules are spatially isolated on a solid surface, after which
they are amplified in parallel by bridge PCR to form separate
clonal populations, or clusters, and then sequenced, as described
in Bentley et al (cited above) and in manufacturer's instructions
(e.g. TruSeq.TM. Sample Preparation Kit and Data Sheet, Illumina,
Inc., San Diego, Calif., 2010); and further in the following
references: U.S. Pat. Nos. 6,090,592; 6,300,070; 7,115,400; and
EP0972081B1; which are incorporated by reference. In one
embodiment, individual molecules disposed and amplified on a solid
surface form clusters in a density of at least 10.sup.5 clusters
per cm.sup.2; or in a density of at least 5.times.10.sup.5 per
cm.sup.2; or in a density of at least 10.sup.6 clusters per
cm.sup.2. In one embodiment, sequencing chemistries are employed
having relatively high error rates. In such embodiments, the
average quality scores produced by such chemistries are
monotonically declining functions of sequence read lengths. In one
embodiment, such decline corresponds to 0.5 percent of sequence
reads have at least one error in positions 1-75; 1 percent of
sequence reads have at least one error in positions 76-100; and 2
percent of sequence reads have at least one error in positions
101-125.
[0057] In one aspect, a sequence-based clonotype profile of an
individual is obtained using the following steps: (a) obtaining a
nucleic acid sample from T-cells and/or B-cells of the individual;
(b) spatially isolating individual molecules derived from such
nucleic acid sample, the individual molecules comprising at least
one template generated from a nucleic acid in the sample, which
template comprises a somatically rearranged region or a portion
thereof, each individual molecule being capable of producing at
least one sequence read; (c) sequencing said spatially isolated
individual molecules; and (d) determining abundances of different
sequences of the nucleic acid molecules from the nucleic. acid
sample to generate the clonotype profile. In one embodiment, each
of the somatically rearranged regions comprise a V region and a J
region. In another embodiment, the step of sequencing comprises
bidirectionally sequencing each of the spatially isolated
individual molecules to produce at least one forward sequence read
and at least one reverse sequence read. Further to the latter
embodiment, at least one of the forward sequence reads and at least
one of the reverse sequence reads have an overlap region such that
bases of such overlap region are determined by a reverse
complementary relationship between such sequence reads. In still
another embodiment, each of the somatically rearranged regions
comprise a V region and a J region and the step of sequencing
further includes determining a sequence of each of the individual
nucleic acid molecules from one or more of its forward sequence
reads and at least one reverse sequence read starting from a
position in a J region and extending in the direction of its
associated V region. In another embodiment, individual molecules
comprise nucleic acids selected from the group consisting of
complete IgH molecules, incomplete IgH molecules, complete IgK
complete, IgK inactive molecules, TCR.beta. molecules, TCR.gamma.
molecules, complete TCR.delta. molecules, and incomplete TCR.delta.
molecules. In another embodiment, the step of sequencing comprises
generating the sequence reads having monotonically decreasing
quality scores. Further to the latter embodiment, monotonically
decreasing quality scores are such that the sequence reads have
error rates no better than the following: 0.2 percent of sequence
reads contain at least one error in base positions 1 to 50, 0.2 to
1.0 percent of sequence reads contain at least one error in
positions 51-75, 0.5 to 1.5 percent of sequence reads contain at
least one error in positions 76-100. In another embodiment, the
above method comprises the following steps: (a) obtaining a nucleic
acid sample from T-cells and/or B-cells of the individual; (b)
spatially isolating individual molecules derived from such nucleic
acid sample, the individual molecules comprising nested sets of
templates each generated from a nucleic acid in the sample and each
containing a somatically rearranged region or a portion thereof,
each nested set being capable of producing a plurality of sequence
reads each extending in the same direction and each starting from a
different position on the nucleic acid from which the nested set
was generated; (c) sequencing said spatially isolated individual
molecules; and (d) determining abundances of different sequences of
the nucleic acid molecules from the nucleic acid sample to generate
the clonotype profile. In one embodiment, the step of sequencing
includes producing a plurality of sequence reads for each of the
nested sets. In another embodiment, each of the somatically
rearranged regions comprise a V region and a J region, and each of
the plurality of sequence reads starts from a different position in
the V region and extends in the direction of its associated J
region.
[0058] In one aspect, for each sample from an individual, the
sequencing technique used in the methods of the invention generates
sequences of least 1000 clonotypes per run; in another aspect, such
technique generates sequences of at least 10,000 clonotypes per
run; in another aspect, such technique generates sequences of at
least 100,000 clonotypes per run; in another aspect, such technique
generates sequences of at least 500,000 clonotypes per run; and in
another aspect, such technique generates sequences of at least
1,000,000 clonotypes per run. In still another aspect, such
technique generates sequences of between 100,000 to 1,000,000
clonotypes per run per individual sample.
[0059] The sequencing technique used in the Methods of the provided
invention can generate about 30 bp, about 40 bp, about 50 bp, about
60 bp, about 70 bp, about 80 bp, about 90 bp, about 100 bp, about
110, about 120 by per read, about 150 bp, about 200 bp, about 250
bp, about 300 bp, about 350 bp, about 400 bp, about 450 bp, about
500 bp, about 550 bp, or about 600 by per read.
Clonotype Determination from Sequence Data
[0060] In one aspect of the invention, sequences of clonotypes
(including but not limited to those derived from IgH, TCR.alpha.,
TCR.beta., TCR.gamma., TCR.delta., and/or IgLK (IgK)) may be
determined by combining information from one or more sequence
reads, for example, along the V(D)J regions of the selected chains.
In another aspect, sequences of clonotypes are determined by
combining information from a plurality of sequence reads. Such
pluralities of sequence reads may include one or more sequence
reads along a sense strand (i.e. "forward" sequence reads) and, one
or more sequence reads along, its complementary strand (i.e.
"reverse" sequence reads). When multiple sequence reads are
generated along the same strand, separate templates are first
generated by amplifying sample molecules with primers selected for
the different positions of the sequence reads. This concept is
illustrated in FIG. 4A where primers (404, 406 and 408) are
employed to generate amplicons (410, 412, and 414, respectively) in
a single reaction. Such amplifications may be carried out in the
same reaction or in separate reactions. In one aspect, whenever PCR
is employed, separate amplification reactions arc used for
generating the separate templates which, in turn, are combined and
used to generate multiple sequence reads along the same strand.
This latter approach is preferable for avoiding the need to balance
primer concentrations (and/or other reaction parameters) to ensure
equal amplification of the multiple templates (sometimes referred
to herein as "balanced amplification" or "unbias amplification").
The generation of templates in separate reactions is illustrated in
FIGS. 4B-4C. There a sample containing IgH (400) is divided into
three portions (472, 474, and 476) which arc added to separate PCRs
using J region primers (401) and V region primers (404, 406, and
408, respectively) to produce amplicons (420, 422 and 424,
respectively). The latter amplicons are then combined (478) in
secondary PCR (480) using P5 and P7 primers to prepare the
templates (482) for bridge PCR and sequencing on an Illumina GA
sequencer, or like instrument.
[0061] Sequence reads of the invention may have a wide variety of
lengths, depending in part on the sequencing technique being
employed. For example, for some techniques, several trade-offs may
arise in its implementation, for example, (i) the number and
lengths of sequence reads per template and (ii) the cost and
duration of a sequencing operation. In one embodiment, sequence
reads are in the range of from 20 to 400 nucleotides: in another
embodiment, sequence reads are in a range of from 30 to 200
nucleotides; in still another embodiment, sequence reads arc in the
range of from 30 to 120 nucleotides. In one embodiment, 1 to 4
sequence reads are generated for determining the sequence of each
clonotype; in another embodiment, 2 to 4 sequence reads arc
generated for determining the sequence of each clonotype; and in
another embodiment, 2 to 3 sequence reads are generated for
determining the sequence of each clonotype. In the foregoing
embodiments, the numbers given are exclusive of sequence reads used
to identify samples from different individuals. The lengths of the
various sequence reads used in the embodiments described below may
also vary based on the information that is sought to be captured by
the read; for example, the starting location and length of a
sequence read may be designed to provide the length of an NDN
region as well as its nucleotide sequence: thus, sequence reads
spanning the entire NDN region arc selected. In other aspects, one
or more sequence reads that in combination (but not separately)
encompass a D and/or NDN region arc sufficient.
[0062] In another aspect of the invention, sequences of clonotypes
are determined in part by aligning sequence reads to one or more V
region reference sequences and one or more J region reference
sequences, and in part by base determination without alignment to
reference sequences, such as in the highly variable NDN region. A
variety of alignment algorithms may be applied to the sequence
reads and reference sequences. For example, guidance for selecting
alignment methods is available in Batzogloti, Briefings in
Bioinformatics, 6: 6-22 (2005), which is incorporated by reference.
In one aspect, whenever V reads or C reads (as mentioned above) are
aligned to V and J region reference sequences, a tree search
algorithm is employed, e.g. as described generally in Gustield
(cited above) and Cormen et al, Introduction to Algorithms, Third
Edition (The MIT Press, 2009).
[0063] In another aspect, an end of at least one forward read and
an end of at least one reverse read overlap in an overlap region
(e.g. 308 in FIG. 3B), so that the bases of the reads arc in a
reverse complementary relationship with one another. Thus, for
example, if a forward read in the overlap region is "5'-acgttge",
then a reverse read in a reverse complementary relationship is
"5'-gcaacgt" within the same overlap region. In one aspect, bases
within such an overlap region arc determined, at least in part,
from such a reverse complementary relationship. That is, a
likelihood of a base call (or a related quality score) in a
prospective overlap region is increased if it preserves,'or is
consistent with, a reverse complementary relationship between the
two sequence reads. In one aspect, clonotypes of TCR .beta. and IgH
chains (illustrated in FIG. 3B) are determined by at least one
sequence read starting in its J region and extending in the
direction of its associated V region (referred to herein as "C
read" (304)) and at least one sequence read starting in its V
region and extending in the direction of its associated J region
(referred to herein as a "V read" (306)). Overlap region (308) may
or may not encompass the NDN region (315) as shown in FIG. 3B.
Overlap region (308) may be entirely in the J region, entirely in
the NDN region, entirely in the V region, or it may encompass a J
region-NDN region boundary or a V region-NDN region boundary, or
both such boundaries (as illustrated in FIG. 3B). Typically, such
sequence reads arc generated by extending sequencing primers, e.g.
(302) and (310) in FIG. 3B, with a polymerase in a
sequencing-by-synthesis reaction, e.g. Metzger, Nature Reviews
Genetics, 11: 31-46 (2010); Fuller et al, Nature Biotechnology, 27:
1013-1023 (2009). The binding sites for primers (302) and (310) are
predetermined, so that they can provide a starting point or
anchoring point for initial alignment and analysis, of the sequence
reads. In one embodiment, a C read is positioned so that it
encompasses the D and/or NDN region of the TCR or IgH chain and
includes a portion of the adjacent V region, e.g. as illustrated in
FIGS. 3B and 3C. In one aspect, the overlap of the V read and the C
read in the V region is used to align the reads with one another.
In other embodiments, such alignment of sequence reads is not
necessary, e.g. with TCR.beta. chains, so that a V read may only be
long enough to identify the particular V region of a clonotype.
This latter aspect is illustrated in FIG. 3C. Sequence read (330)
is used to identify a V region, with or without overlapping another
sequence read, and another sequence read (332) traverses the NDN
region and is used to determine the sequence thereof. Portion (334)
of sequence read (332) that extends into the V region is used to
associate the sequence information of sequence read (332) with that
of sequence read (330) to determine a clonotype. For some
sequencing methods, such as base-by-base approaches like the Solexa
sequencing method, sequencing run time and reagent costs are
reduced by minimizing the number of sequencing cycles in an
analysis. Optionally, as illustrated in FIG. 3B, amplicon (300) is
produced with sample tag (312) to distinguish between clonotypes
originating from different biological samples, e.g. different
patients. Sample tag (312) may be identified by annealing a primer
to primer binding region (316) and extending it (314) to produce a
sequence read across tag (312), from which sample tag (312) is
decoded.
[0064] The IgH chain is more challenging to analyze than TCR.beta.
chain because of at least two factors: i) the presence of somatic
mutations makes the mapping or alignment more difficult, and ii)
the NDN region is larger so that it is often not possible to map a
portion of the V segment to the C read. In one aspect of the
invention, this problem is overcome by using a plurality of primer
sets for generating V reads, which are located at different
locations along the V region, preferably so that the primer binding
sites are nonoverlapping and spaced apart, and with at least one
primer binding site adjacent to the NDN region, e.g. in one
embodiment from 5 to 50 bases from the V-NDN junction, or in
another embodiment from 10 to 50 bases from the V-NDN junction. The
redundancy of a plurality of primer sets minimizes the risk of
failing to detect a clonotype due to a failure of one or two
primers having binding sites affected by somatic mutations. In
addition, the presence of at least one primer binding site adjacent
to the NDN region makes it more likely that a V read will overlap
with the C read and hence effectively extend the length of the C
read. This allows for the generation of a continuous sequence that
spans all sizes of NDN regions and that can also map substantially
the entire V and J regions on both sides of the NDN region.
Embodiments for carrying out such a scheme are illustrated in FIGS.
4A and 4D. In FIG. 4A, a sample comprising IgH chains (400) are
sequenced by generating a plurality amplicons for each chain by
amplifying the chains with a single set of J region primers (401)
and a plurality (three shown) of sets of V region (402) primers
(404, 406, 408) to produce a plurality of nested amplicons (e.g.,
410, 412, 416) all comprising the same NDN region and having
different lengths encompassing successively larger portions (411,
413, 415) of V region (402). Members of a nested set may be grouped
together after sequencing by noting the identify (or substantial
identity) of their respective NDN, J and/or C regions, thereby
allowing reconstruction of a longer V(D)J segment than would be the
case otherwise for a sequencing platform with limited read length
and/or sequence quality. In one embodiment, the plurality of primer
sets may be a number in the range of from 2 to 5. In another
embodiment the plurality is 2-3; and still another embodiment the
plurality is 3. The concentrations and positions of the primers in
a plurality may vary widely. Concentrations of the V region primers
may or may not be the same. In one embodiment, the primer closest
to the NDN region has a higher concentration than the other primers
of the plurality, e.g. to insure that amplicons containing the NDN
region are represented in the resulting amplicon. In a particular
embodiment where a plurality a three primers is employed, a
concentration ratio of 60:20:20 is used. One or more primers (e.g.
435 and 437 in FIG. 4B) adjacent to the NDN region (444) may be
used to generate one or more sequence reads (e.g. 434 and 436) that
overlap the sequence read (442) generated by J region primer (432),
thereby improving the quality of base calls in overlap region
(440). Sequence reads from the plurality of primers may or may not
overlap the adjacent downstream primer binding site and/or adjacent
downstream sequence read. In one embodiment, sequence reads
proximal to the NDN region (e.g. 436 and 438) may be used to
identify the particular V region associated with the clonotype.
Such a plurality of primers reduces the likelihood of incomplete or
failed amplification in case one of the primer binding sites is
hypermutated during immunoglobulin development. It also increases
the likelihood that diversity introduced by hypermutation of the V
region will be capture in a clonotype sequence. A secondary PCR may
be performed to prepare the nested amplicons for sequencing, e.g.
by amplifying with the P5 (401) and P7 (404, 406, 408) primers as
illustrated to produce amplicons (420, 422, and 424), which may be
distributed as single molecules on a solid surface, where they are
further amplified by bridge PCR, or like technique.
[0065] Base calling in NDN regions (particularly of IgH chains) can
be improved by using the codon stricture of the flanking J and V
regions, as illustrated in FIG. 4E. (As used herein,
"codon.structure" means the codons of the natural reading frame of
segments of TCR or BCR transcripts or genes outside of the NDN
regions, e.g. the V region, J region, or the like.) There amplicon
(450), which is an enlarged view of the amplicon of FIG. 4B, is
shown along with the relative positions of C read (442) and
adjacent V read (434) above and the codon structures (452 and 454)
of V region (430) and J region (446), respectively, below. In
accordance with this aspect of the invention, after the codon
structures (452 and 454) are identified by conventional alignment
to the V and J reference sequences, bases in NDN region (456) are
called (or identified) one base at a time moving from J region
(446) toward V region (430) and in the opposite direction from V
region (430) toward J region (446) using sequence reads (434) and
(442). Under normal biological conditions, only the recombined TCR
or IgH sequences that have in frame codons from the V region
through the NDN region and to the J region are expressed as
proteins. That is, of the variants generated somatically only ones
expressed are those whose J region and V region codon frames are
in-frame with one another and remain in-frame through the NDN
region. (Here the correct frames of the V and J regions arc
determined from reference sequences). If an out-of-frame sequence
is identified based one or more low quality base calls, the
corresponding clonotype is flagged for re-evaluation or as a
potential disease-related anomaly. If the sequence identified is
in-frame and based on high quality base calls, then there is
greater confidence that the corresponding clonotype has been
correctly called. Accordingly, in one aspect, the invention
includes a method of determining V(D)J-based clonotypes from
bidirectional sequence reads comprising the steps of: (a)
generating at least one J region sequence read that begins in a J
region and extends into an NDN region and at least one V region
sequence read that begins in the V regions and extends toward the
NDN region such that the J region sequence read and the V region
sequence read are overlapping in an overlap region, and the J
region and the V region each have a codon structure; (b)
determining whether the codon structure of the J region extended
into the NDN region is in frame with the codon structure of the V
region extended toward the NDN region. In a further embodiment, the
step of generating includes generating at least one V region
sequence read that begins in the V region and extends through the
NDN region to the J region, such that the J region sequence read
and the V region sequence read arc overlapping in an overlap
region.
[0066] Somatic Hypermutations. In one embodiment, IgH-based
clonotypes that have undergone somatic hypermutation are determined
as follows: A somatic mutation is defined as a sequenced base that
is different from the corresponding base of a reference sequence
(of the relevant segment, usually V, J or C) and that is present in
a statistically significant number of reads. In one embodiment, C
reads may be used to find somatic mutations with respect to the
mapped J segment and likewise V reads for the V segment. Only
pieces of the C and V reads are used that are either directly
mapped to J or V segments or that are inside the clonotype
extension up to the NDN boundary. In this way, the NDN region is
avoided and the same `sequence information` is not used for
mutation finding that was previously used for clonotype
determination (to avoid erroneously classifying as mutations
nucleotides that arc really just different recombined NDN regions).
For each segment type, the mapped segment (major allele) is used as
a scaffold and all reads are considered which have mapped to this
allele during the read mapping phase. Each position of the
reference sequences where at least one read has mapped is analyzed
for somatic mutations. In one embodiment, the criteria for
accepting a non-reference base as a valid mutation include the
following: 1) at least N reads with the given mutation base, 2) at
least a given fraction N/M reads (where M is the total number of
mapped reads at this base position) and 3) a statistical cut based
on the binomial distribution, the average Q score of the N reads at
the mutation base as well as the number (M-N) of reads with a
non-mutation base. Preferably, the above parameters arc selected so
that the false discovery rate of mutations per clonotype is less
than 1 in 1000, and more preferably, less than 1 in 10000.
[0067] Phylogenic Clonotypes (Clans). In cancers, such as lymphoid
neoplasms, a single lymphocyte progenitor may give rise to many
related lymphocyte progeny, each possessing and/or expressing a
slightly different TCR or BCR, and therefore a different clonotype,
due to cancer-related somatic mutation(s), such as base
substitutions, aberrant rearrangements, or the like. Cells
producing such clonotypes are referred to herein as phylogenic
clones, and a set of such related clones are referred to herein as
a "clan." Likewise, clonotypes of phylogenic clones are referred to
as phylogenic clonotypes and a set of phylogenic clonotypes may be
referred to as a clan of clonotypes. In one aspect, methods of the
invention comprise monitoring the frequency of a clan of clonotypes
(i.e., the sum of frequencies of the constituent phylogenic
clonotypes of the clan), rather than a frequency of an individual
clonotype. Phylogenic clonotypes may be identified by one or more
measures of relatedness to a parent clonotype. In one embodiment,
phylogenic clonotypes may be grouped into the same clan by percent
homology, as described more fully below. In another embodiment,
phylogenic clonotypes are identified by common usage of V regions,
J regions, and/or NDN regions. For example, a clan may be defined
by clonotypes having common J and ND regions but different V
regions; or it may be defined by clonotypes having the same V and J
regions (including identical base substitutions mutations) but with
different NDN regions; or it may be defined by a clonotype-that has
undergone one or more insertions and/or deletions of from 1-10
bases, or from 1-5 bases, or from 1-3 bases, to generate clan
members. In another embodiment, members of a clan are determined as
follows. Clonotypes are assigned to the same clan if they satisfy
the following criteria: i) they are mapped to the same V and J
reference segments, with the mappings occurring at the same
relative positions in the clonotype sequence, and ii) their NDN
regions arc substantially identical. "Substantial" in reference to
clan membership means that some small differences in the NDN region
are allowed because somatic mutations may have occurred in this
region. Preferably, in one embodiment, to avoid falsely calling a
mutation in the NDN region, whether a base substitution is accepted
as a cancer-related mutation depends directly on the size of the
NDN region of the clan. For example, a method may accept a
clonotype as a clan member if it has a one-base difference from
clan NDN sequence(s) as a cancer-related mutation if the length of
the clan NDN sequence(s) is m nucleotides or greater, e.g. 9
nucleotides or greater, otherwise it is not accepted, or if it has
a two-base difference from clan NDN sequence(s) as cancer-related
mutations if the length of the clan NDN sequence(s) is n
nucleotides or greater, e.g. 20 nucleotides or greater, otherwise
it is not accepted, In another embodiment, members of a clan are
determined using the following criteria: (a) V read maps to the
same V region, (b) C read maps to the same J region, (c) NDN region
substantially identical (as described above), and (d) position of
NDN region between V-NDN boundary and J-NDN boundary is the same
(or equivalently, the number of downstream base additions to D and
the number of upstream base additions to D are the same).
Clonotypes of a single sample may be grouped into clans and, clans
from successive samples acquired at different times may be compared
with one another. In particular; in one aspect of the invention,
clans containing clonotypes correlated with a disease, such as a
lymphoid neoplasm, are identified from clonotypes of each sample
and compared with that of the immediately previous sample to
determine disease status, such as, continued remission, incipient
relapse, evidence of further clonal evolution, or the like.
[0068] It is expected that PCR error is concentrated in some bases
that were mutated in the early cycles of PCR. Sequencing error is
expected to be distributed in many bases even though it is totally
random as the error is likely to have some systematic biases. It is
assumed that some bases will have sequencing error at a higher
rate, say 5% (5 fold the average). Given these assumptions,
sequencing error becomes the dominant type of error. Distinguishing
PCR errors from the occurrence of highly related clonotypes will
play a role in analysis. Given the biological significance to
determining that there are two or more highly related clonotypes, a
conservative approach to making such calls is taken. The detection
of enough of the minor clonotypes so as to be sure with high
confidence (say 99.9%) that there are more than one clonotype is
considered. For example of clonotypes that are present at 100
copies/1,000,000, the minor variant is detected 14 or more times
for it to be designated as an independent clonotype. Similarly, for
clonotypes present at 1,000 copies/1,000,000 the minor variant can
be detected 74 or more times to be designated as an independent
clonotype. This algorithm can be enhanced by using the base quality
score that is obtained with each sequenced base. If the
relationship between quality score and error rate is validated
above, then instead of employing the conservative 5% error rate for
all bases, the quality score can be used to decide the number of
reads that need to be present to call an independent clonotype. The
median quality score of the specific base in all the reads can be
used, or more rigorously, the likelihood of being an error can be
computed given the quality score of the specific base in each read,
and then the probabilities can be combined (assuming independence)
to estimate the likely number of sequencing error for that base. As
a result, there are different thresholds of rejecting the
sequencing error hypothesis for different bases with different
quality scores. For example for a clonotype present at 1,000
copies/1,000,000 the minor variant is designated independent when
it is detected 22 and 74 times if the probability of error were
0.01 and 0.05, respectively.
EXAMPLE
TCR.beta. Repertoire Analysis: Amplification and Sequencing
Strategy
[0069] In this example, TCR.beta. chains are analyzed. The analysis
includes amplification, sequencing, and analyzing the TCR.beta.
sequences. One primer is complementary to a common sequence in
C.beta.1 and C.beta.2, and there arc 34 V primers capable of
amplifying all 48 V segments. C.beta.1 or C.beta.2 differ from each
other at position 10 and 14 from the J/C junction. The primer for
C.beta.1 and C.beta.2 ends at position 16 by and has no preference
for C.beta.1 or C.beta.2. The 34 V primers are modified from an
original set of primers disclosed in Van Dongen et al, U.S. patent
publication 2006/0234234, which is incorporated herein by
reference. The modified primers arc disclosed in Faham et al, U.S.
patent publication 2010/0151471, which is also incorporated herein
by reference.
[0070] The Illumina Genome Analyzer is used to sequence the
amplicon produced by the above primers. A two-stage amplification
is performed on messenger RNA transcripts (200), as illustrated in
FIGS. 2A-2B, the first stage employing the above primers and a
second stage to add common primers for bridge amplification and
sequencing. As shown in FIG. 2A, a primary PCR is performed using
on one side a 20 by primer (202) whose 3' end is 16 bases from the
J/C junction (204) and which is perfectly complementary to
C.beta.1(203) and the two alleles of C.beta.2. In the V region
(206) of RNA transcripts (200), primer set (212) is provided which
contains primer sequences complementary to the different V region
sequences (34 in one embodiment). Primers of set (212) also contain
a non-complementary tail (214) that produces amplicon (216) having
primer binding site (218) specific for P7 primers (220). After a
conventional multiplex PCR, amplicon (216) is formed that contains
the highly diverse portion of the J(D)V region (206, 208, and 210)
of the mRNA transcripts and common primer binding sites (203 and
218) for a secondary amplification to add a sample tag (221) and
primers (220 and 222) for cluster formation by bridge PCR. In the
secondary PCR, on the same side of the template, a primer (222 in
FIG. 2B and referred to herein as "C10-17-P5") is used that has at
its 3'end the sequence of the 10 bases closest to the J/C junction,
followed by 17 bp with the sequence of positions 15-31 from the J/C
junction, followed by the PS sequence (224), which plays a role in
cluster formation by bridge PCR in Solexa sequencing. (When the
C10-17-P5 primer (222) anneals to the template generated from the
first PCR, a 4 by loop (position 11-14) is created in the template,
as the primer hybridizes to the sequence of the 10 bases closest to
the J/C junction and bases at positions 15-31 from the J/C
junction. The looping of positions 11-14 eliminates differential
amplification of templates carrying C.beta.1 or C.beta.2.
Sequencing is then done with a primer complementary to the sequence
of the 10 bases closest to the J/C junction and bases at positions
15-31 from the J/C junction (this primer is called C'). C10-17-P5
primer can be HPLC purified in order to ensure that all the
amplified material has intact ends that can be efficiently utilized
in the cluster formation.)
[0071] In FIG. 2A, the length of the overhang on the V primers
(212) is preferably 14 bp. The primary PCR is helped with a shorter
overhang (214). Alternatively, for the sake of the secondary PCR,
the overhang in the V primer is used in the primary PCR as long as
possible because the secondary PCR is priming from this sequence. A
minimum size of overhang (214) that supports an efficient secondary
PCR was investigated. Two series of V primers (for two different V
segments) with overhang sires from 10 to 30 with 2 by steps were
made. Using the appropriate synthetic sequences, the first PCR was
performed with each of the primers in the series and gel
electrophoresis was performed to show that all amplified.
[0072] As illustrated in FIG. 2A, the primary PCR uses 34 different
V primers (212) that anneal to V region (206) of RNA templates
(200) and contain a common 14 by overhang on the 5' tail. The 14 by
is the partial sequence of one of the Illumina sequencing primers
(termed the Read 2 primer). The secondary amplification primer
(220) on the same side includes P7 sequence, a tag (221), and Read
2 primer sequence (223) (this primer is called Read2_tagX_P7). The
P7 sequence is used for cluster formation. Read 2 primer and its
complement are used for sequencing the V segment and the tag
respectively. A set of 96 of these primers with tags numbered 1
through 96 arc created (sec below). These primers arc HPLC purified
in order to ensure that all the amplified material has intact ends
that can be efficiently utilized in the cluster formation.
[0073] As mentioned above, the second stage primer, C-10-17-P5
(222, FIG. 2B) has interrupted homology to the template generated
in the first stage PCR. The efficiency of amplification using this
primer has been validated. An alternative primer to C-10-17-P5,
termed CsegP5, has perfect homology to the first stage C primer and
a 5' tail carrying P5. The efficiency of using C-10-17-P5 and
CsegP5 in amplifying first stage. PCR templates was compared by
performing real time PCR. In several replicates, it was found that
PCR using the C-10-17-P5 primer had little or no difference in
efficiency compared with PCR using the CsegP5 primer.
[0074] Amplicon (300) resulting from the 2-stage amplification
illustrated in FIGS. 2A-2B has the structure typically used with
the Illumina sequencer as shown in FIG. 3A. Two primers that anneal
to the outmost part of the molecule, Illumina primers P5 and P7 are
used for solid phase amplification of the molecule (cluster
formation). Three sequence reads arc done per molecule. The first
read of 100 by is done with the C' primer, which has a melting
temperature that is appropriate for the Illumina sequencing
process. The second read is 6 by long only and is solely for the
purpose of identifying the sample tag. It is generated using a tag
primer provided by the manufacturer (Illumina). The final read is
the Read 2 primer, also provided by the manufacturer (Illumina).
Using this primer, a 100 by read in the V segment is generated
starting with the 1st PCR V primer sequence.
[0075] While the present invention has been described with
reference to several particular example embodiments, those skilled
in the art will recognize that many changes may be made thereto
without departing from the spirit and scope of the present
invention. The present invention is applicable to a variety of
sensor implementations and other subject matter, in addition to
those discussed above.
Definitions
[0076] Unless otherwise specifically defined herein, terms and
symbols of nucleic acid chemistry, biochemistry, genetics, and
molecular biology used herein follow those of standard treatises
and texts in the field, e.g. Kornberg and Baker, DNA Replication,
Second Edition (W. H. Freeman, New York, 1992); Lehninger,
Biochemistry, Second Edition (Worth Publishers, New York, 1975);
Strachan and Read, Human Molecular Genetics, Second Edition
(Wiley-Liss, New York, 1999); Abbas et al, Cellular and Molecular
Immunology, 6.sup.th edition (Saunders, 2007).
[0077] "Aligning" means a method of comparing a test sequence, such
as a sequence read, to one or more reference sequences to determine
which reference sequence or which portion of a reference sequence
is closest based on some sequence distance measure. An exemplary
method of aligning nucleotide sequences is the Smith Waterman
algorithm. Distance measures may include Hamming distance,
Levenshtein distance, or the like. Distance measures may include a
component related to the quality values of nucleotides of the
sequences being compared.
[0078] "Amplicon" means the product of a polynucleotide
amplification reaction; that is, a clonal population of
polynucleotides, which may be single stranded or double stranded,
which are, replicated from one or more starting sequences. The one
or more starting sequences may be one or more copies of the same
sequence, or they may be a mixture of different sequences.
Preferably, amplicons are formed by the amplification of a single
starting sequence. Amplicons may be produced by a variety of
amplification reactions whose products comprise replicates of the
one or more starting, or target, nucleic acids. In one aspect,
amplification reactions producing amplicons arc "template-driven"
in that base pairing of reactants, either nucleotides or
oligonucleotides, have complements in a template polynucleotide
that are required for the creation of reaction products. In one
aspect, template-driven reactions are primer extensions with a
nucleic acid polymerase or oligonucleotide ligations with a nucleic
acid ligase. Such reactions include, but arc not limited to,
polymerase chain reactions (PCRs), linear polymerase reactions,
nucleic acid sequence-based amplification (NASBAs), rolling circle
amplifications, and the like, disclosed in the following references
that are incorporated herein by reference: Mullis et al, U.S. Pat.
Nos. 4,683,195; 4,965,188; 4,683,202; 4,800,159 (PCR); Gelfand ct
al, U.S. Pat. No. 5,210,015 (real-time PCR with "taqman" probes);
Wittwer et al, U.S. Pat. No. 6,174,670; Kacian et al, U.S. Pat. No.
5,399,491 ("NASBA"); Lizardi, U.S. Pat. No. 5,854,033; Aono et al,
Japanese patent publ. JP 4-262799 (rolling circle amplification);
and the like. In one aspect, amplicons of the invention are
produced by PCRs. An amplification reaction may be a "real-time"
amplification if a detection chemistry is available that permits a
reaction product to be measured as the amplification reaction
progresses, e.g. "real-time PCR" described below, or "real-time
NASBA" as described in Leone et al, Nucleic Acids Research, 26:
2150-2155 (1998), and like references. As used herein, the term
"amplifying" means performing an amplification reaction. A
"reaction mixture" means a solution containing all the necessary
reactants for performing a reaction, which may include, but not be
limited to, buffering agents to maintain pH at a selected level
during a reaction, salts, co-factors, scavengers, and the like.
[0079] "Clonality" as used herein means a measure of the degree to
which the distribution of clonotype abundances among clonotypes of
a repertoire is skewed to a single or a few clonotypes. Roughly,
clonality is an inverse measure of clonotype diversity. Many
measures or statistics are available from ecology describing
species-abundance relationships that may be used for clonality
measures in accordance with the invention, e.g. Chapters 17 &
18, in Pielou, An Introduction to Mathematical Ecology,
(Wiley-Interscience, 1969). In one aspect, a clonality measure used
with the invention is a function of a clonotype profile (that is,
the number of distinct clonotypes detected and their abundances),
so that after a clonotype profile is measured, clonality may be
computed from it to give a single number. One clonality measure is
Simpson's measure, which is simply the probability that two
randomly drawn clonotypes will be the same. Other clonality
measures include information, based measures and McIntosh's
diversity index, disclosed in Pielou (cited above).
[0080] "Clonotype" means a recombined nucleotide sequence of a T
cell or B cell encoding a T cell receptor (TCR) or B cell receptor
(BCR); or a portion thereof. In one aspect, a collection of all the
distinct clonotypes of a population of lymphocytes of an individual
is a repertoire of such population, e.g. Arstila et al, Science,
286: 958-961 (1999); Yassai et al, Immunogenetics, 61: 493-502
(2009); Kedzierska et al, Mol. Immunol., 45(3): 607-618 (2008); and
the like. As used herein, "clonotype profile," or "repertoire
profile," is a tabulation of clonotypes of a sample of T cells
and/or B cells (such as a peripheral blood sample containing such
cells) that includes substantially all of the repertoire's
clonotypes and their relative abundances. "Clonotype profile,"
"repertoire profile," and "repertoire" are used herein
interchangeably. (That is, the term "repertoire," as discussed more
fully below, means a repertoire measured from a sample of
lymphocytes). In one aspect of the invention, clonotypes comprise
portions of an immunoglobulin heavy chain (IgH) or a TCR .beta.
chain. In other aspects of the invention, clonotypes may be based
on other recombined molecules, such as immunoglobulin chains or
TCR.alpha. chains, or portions thereof.
[0081] "Coalescing" means treating two candidate clonotypes with
sequence differences as the same by determining that such
differences are due to experimental or measurement error and not
due to genuine biological differences. In one aspect, a sequence of
a higher frequency candidate clonotype is compared to that of a
lower frequency candidate clonotype and if predetermined criteria
are satisfied then the number of lower frequency candidate
clonotypes is added to that of the higher frequency candidate
clonotype and the lower frequency candidate clonotype is thereafter
disregarded. That is, the read counts associated with the lower
frequency candidate clonotype are added to those of the higher
frequency candidate clonotype.
[0082] "Complementarity determining regions" (CDRs) mean regions of
an immunoglobulin (i.e., antibody) or T cell receptor where the
molecule complements an antigen's conformation, thereby determining
the molecule's specificity and contact with a specific antigen. T
cell receptors and immunoglobulins each have three CDRs: CDR1 and
CDR2 are found in the variable (V) domain, and CDR3 includes some
of V, all of diverse (D) (heavy chains only) and joint (J), and
some of the constant (C) domains.
[0083] "Data structure" means an organization of information,
usually in a computer or memory device, for better algorithm
efficiency. Exemplary data structures include queues, stacks,
linked lists, heaps, hash tables, arrays, trees, and the like. Data
structures may have substructures that correspond to units of
information or to subsets of related information. For example,
arrays have rows and columns of entries; trees have nodes,
branches, subtrees, and leaves; or the like. In one aspect, a data
structure used herein is a sequence tree, an array or a hash
table.
[0084] "Lymphoid neoplasm" means an abnormal proliferation of
lymphocytes that may be malignant or non-malignant. A lymphoid
cancer is a malignant lymphoid neoplasm. Lymphoid neoplasms arc the
result of, or are associated with, lymphoproliferative disorders,
including but not limited to, follicular lymphoma, chronic
lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), hairy
cell leukemia, lymphomas, multiple myeloma, post-transplant
lymphoproliferative disorder, mantle lymphoma (MCL), diffuse large
B cell lymphoma (DLBCL), T cell lymphoma, or the like; e.g. Jaffe
et al, Blood, 112:4384-4399 (2008); Swerdlow et al, WHO
Classification of Tumours of Haematopoietic and Lymphoid Tissues
(e. 4.sup.th) (IARC Press, 2008).
[0085] "Percent homologous," "percent identical," or like terms
used in reference to the comparison of a reference sequence and
another sequence ("comparison sequence") mean that in an optimal
alignment between the two sequences, the comparison sequence is
identical to the reference sequence in a number of subunit
positions equivalent to the indicated percentage, the subunits
being nucleotides for polynucleotide comparisons or amino acids for
polypeptide comparisons. As used herein, an "optimal alignment" of
sequences being compared is one that maximizes matches between
subunits and minimizes the number of gaps employed in constructing
an alignment. Percent identities may be determined with
commercially available implementations of algorithms, such as that
described by Needleman and Wunsch, J. Mol. Biol., 48: 443-453
(1970) ("GAP" program of Wisconsin Sequence Analysis Package,
Genetics Computer Group, Madison, Wis.), or the like. Other
software packages in the art for constructing alignments and
calculating percentage identity or other measures of similarity
include the "BestFit" program, based'on the algorithm of Smith and
Waterman, Advances in Applied Mathematics, 2: 482-489 (1081)
(Wisconsin Sequence Analysis Package, Genetics Computer Group,
Madison, Wis.). In other words, for example, to obtain a
polynucleotide having a nucleotide sequence at least 95 percent
identical to a reference nucleotide sequence, up to five percent of
the nucleotides in the reference sequence may be deleted or
substituted with another nucleotide, or a number of nucleotides up
to five percent of the total number of nucleotides in the reference
sequence may be inserted into the reference sequence.
[0086] "Polymerase chain reaction," or "PCR," means a reaction for
the in vitro amplification of specific DNA sequences by the
simultaneous primer extension of complementary strands of DNA. In
other words, PCR is a reaction for making multiple copies or
replicates of a target nucleic acid flanked by primer binding
sites, such reaction comprising one or more repetitions of the
following steps: (i) denaturing the target nucleic acid, (ii)
annealing primers to the primer binding sites, and (iii) extending
the primers by a nucleic acid polymerase in the presence of
nucleoside triphosphates. Usually, the reaction is cycled through
different temperatures optimized for each step in a thermal cycler
instrument. Particular temperatures, durations at each step, and
rates of change between steps depend on many factors well-known to
those of ordinary skill in the art, e.g. exemplified by the
references: McPherson et al, editors, PCR: A Practical Approach and
PCR2: A Practical Approach (IRL Press, Oxford, 1991 and 1995,
respectively). For example, in a conventional PCR using Taq DNA
polymerase, a double stranded target nucleic acid may be denatured
at a temperature >90.degree. C., primers annealed at a
temperature in the range 50-75.degree. C., and primers extended at
a temperature in the range 72-78.degree. C. The term "PCR"
encompasses derivative forms of the reaction, including but not
limited to, RT-PCR, real-time PCR, nested PCR, quantitative PCR,
multiplexed PCR, and the like. Reaction volumes range from a few
hundred nanoliters, e.g. 200 nL, to a few hundred .mu.L, e.g. 200
.mu.L. "Reverse transcription PCR," or "RT-PCR," means a PCR that
is preceded by a reverse transcription reaction that converts a
target RNA to a complementary single stranded DNA, which is then
amplified, e.g. Tecott et al, U.S. Pat. No. 5,168,038, which patent
is incorporated herein by reference. "Real-time PCR" means a PCR
for which the amount of reaction product, i.e. amplicon, is
monitored as the reaction proceeds. There are many forms of
real-time PCR that differ mainly in the detection chemistries used
for monitoring the reaction product, e.g. Gelfand et al, U.S. Pat.
No. 5,210,015 ("taqman"); Wittwer et al, U.S. Pat. Nos. 6,174,670
and 6,569,627 (intercalating dyes); Tyagi et al, U.S. Pat. No.
5,925,517 (molecular beacons); which patents are incorporated
herein by reference. Detection chemistries for real-time PCR are
reviewed in Mackay et al, Nucleic Acids Research, 30: 1292-1305
(2002), which is also incorporated herein by reference. "Nested
PCR" means a two-stage PCR wherein the amplicon of a first PCR
becomes the sample for a second PCR using a new set of primers, at
least one of which binds to an interior location of the first
amplicon. As used herein, "initial primers" in reference to a
nested amplification reaction mean the printers used to generate a
first amplicon, and "secondary primers" mean the one or more
primers used to generate a second, or nested, amplicon.
"Multiplexed PCR" means a PCR wherein multiple target sequences (or
a single target sequence and one or more reference sequences) are
simultaneously carried out in the same reaction mixture, e.g.
Bernard ct al, Anal. Biochem., 273: 221-228 (1999) (two-color
real-time PCR). Usually, distinct sets of primers are employed for
each sequence being amplified. Typically, the number of target
sequences in a multiplex PCR is in the range of from 2 to 50, or
from 2 to 40, or from 2 to 30. "Quantitative PCR" means a PCR
designed to measure the abundance of one or more specific target
sequences in a sample or specimen. Quantitative PCR includes both
absolute quantitation and relative quantitation of such target
sequences. Quantitative measurements are made using one or more
reference sequences or internal standards that may be assayed
separately or together with a target sequence. The reference
sequence may be endogenous or exogenous to a sample or specimen,
and in the latter case, may comprise one or more competitor
templates. Typical endogenous reference sequences include segments
of transcripts of the following genes: .beta.-actin, GAPDH,
.beta..sub.2-microglobulin, ribosomal RNA, and the like. Techniques
for quantitative PCR are well-known to those of ordinary skill in
the art, as exemplified in the following references that are
incorporated by reference: Freeman et al, Biotechniques, 26:
112-126 (1999); Becker-Andre et al, Nucleic Acids Research, 17:
9437-9447 (1989); Zimmerman et al, Biotechniques, 21: 268-279
(1996); Diviacco et al, Gene, 122: 3013-3020 (1992); Becker-Andre
et al, Nucleic Acids Research, 17: 9437-9446 (1989); and the
like.
[0087] "Primer" means an oligonucleotide, either natural or
synthetic that is capable, upon forming a duplex with a
polynucleotide template, of acting as a point of initiation of
nucleic acid synthesis and being extended from its 3' end along the
template so that an extended duplex is formed. Extension of a
primer is usually carried out with a nucleic acid polymerase, such
as a DNA or RNA polymerase. The sequence of nucleotides added in
the extension process is determined by the sequence of the template
polynucleotide. Usually primers arc extended by a DNA polymerase.
Primers usually have a length in the range of from 14 to 40
nucleotides, or in the range of from 18 to 36 nucleotides. Primers
are employed in a variety of nucleic amplification reactions, for
example, linear amplification reactions using a single primer, or
polymerase chain reactions, employing two or more primers. Guidance
for selecting the lengths and sequences of primers for particular
applications is well known to those of ordinary skill in the art,
as evidenced by the following references that are incorporated by
reference: Dieffenbach, editor, PCR Primer: A Laboratory Manual,
2.sup.nd Edition (Cold Spring Harbor Press, New York, 2003).
[0088] "Quality score" means a measure of the probability that a
base assignment at a particular sequence location is correct. A
variety methods are well known to those of ordinary skill for
calculating quality scores for particular circumstances, such as,
for bases called as a result of different sequencing chemistries,
detection systems, base-calling algorithms, and so on. Generally,
quality score values arc monotonically related to probabilities of
correct base calling. For example, a quality score, or Q, of 10 may
mean that there is a 90 percent chance that a base is called
correctly, a Q of 20 may mean that there is a 99 percent chance
that a base is called correctly, and so on. For some sequencing
platforms, particularly those using sequencing-by-synthesis
chemistries, average quality scores decrease as a function of
sequence read length, so that quality scores at the beginning of a
sequence read are higher than those at the end of a sequence read,
such declines being due to phenomena such as incomplete extensions,
carry forward extensions, loss of template, loss of polymerase,
capping failures, deprotection failures, and the like.
[0089] "Repertoire", or "immune repertoire", means a set of
distinct recombined nucleotide sequences that encode T cell
receptors (TCRs) or B cell receptors (BCRs), or fragments thereof,
respectively; in a population Oft lymphocytes of an individual,
wherein the nucleotide sequences of the set have a one-to-one
correspondence with distinct lymphocytes or their subpopulations
for substantially all of the lymphocytes of the population. In one
aspect, a population of lymphocytes from which a repertoire is
determined is taken from one or more tissue samples, such as one or
more blood samples. A member nucleotide sequence of a repertoire is
referred to herein as a "clonotype." In one aspect, clonotypes of a
repertoire comprises any segment of nucleic acid common to a T cell
or a B cell population which has undergone somatic recombination
during the development of TCRs or BCRs, including normal or
aberrant (e.g. associated with cancers) precursor molecules
thereof, including, but not limited to, any of the following: an
immunoglobulin heavy chain (IgH) or subsets thereof (e.g. an IgH
variable region, CDR3 region, or the like), incomplete IgH
molecules, an immunoglobulin light chain or subsets thereof (e.g. a
variable region, CDR region, or the like), T cell receptor a chain
or subsets thereof, T cell receptor .beta. chain or subsets thereof
(e.g. variable region, CDR3, V(D)J region, or the like), a CDR
(including CDR1, CDR2 or CDR3, of either TCRs or BCRs, or
combinations of such CDRs), V(D)J regions of either TCRs or BCRs,
hypermutated regions of IgH variable regions. or the like. In one
aspect, nucleic acid segments defining clonotypes of a repertoire
arc selected so that their diversity (i.e. the number of distinct
nucleic acid sequences in the set) is large enough so that
substantially every T cell or B cell or clone thereof in an
individual carries a unique nucleic acid sequence of such
repertoire. That is, in accordance with the invention, a
practitioner may select for defining clonotypes a particular
segment or region of recombined nucleic acids that encode TCRs or
BCRs that do not reflect the full diversity of a population of T
cells or B cells; however, preferably, clonotypes are defined so
that they do reflect the diversity of the population of T cells
and/or B cells from which they are derived. That is, preferably
each different clone of a sample has different clonotype. (Of
course, in some applications, there will be multiple copies of one
or more particular clonotypes within a profile, such as in the case
of samples from leukemia or lymphoma patients). In other aspects of
the invention, the population of lymphocytes corresponding to a
repertoire may be circulating B cells, or may be circulating T
cells, or may be subpopulations of either of the foregoing
populations, including but not limited to, CD4+ T cells, or CD8+ T
cells, or other subpopulations defined by cell surface markers, or
the like. Such subpopulations may be acquired by taking samples
from particular tissues, e.g. bone marrow, or lymph nodes, or the
like, or by sorting or enriching cells from a sample (such as
peripheral blood) based on one or more cell surface markers, size,
morphology, or the like. In still other aspects, the population of
lymphocytes corresponding to a repertoire may be derived from
disease tissues, such as a tumor tissue, an infected tissue, or the
like. In one embodiment, a repertoire comprising human TCR .beta.
chains or fragments thereof comprises a number of distinct
nucleotide sequences in the range of from 0.1.times.10.sup.6to
1.8.times.10.sup.6, or in the range of from 0.5.times.10.sup.6 to
1.5.times.10.sup.6, or in the range of from 0.8.times.10.sup.6 to
1.2.times.10.sup.6. In another embodiment, a repertoire comprising
human. IgH chains or fragments thereof comprises a number of
distinct nucleotide sequences in the range of from
0.1.times.10.sup.6 to 1.8.times.10.sup.6, or in the range of from
0.5.times.10.sup.6to 1.5.times.10.sup.6, or in the range of from
0.8.times.10.sup.6to 1.2.times.10.sup.6. In a particular
embodiment, a repertoire of the invention comprises a set of
nucleotide sequences encoding substantially all segments of the
V(D)J region of an IgH chain. In one aspect, "substantially all" as
used herein means every segment having a relative abundance of
0.001 percent or higher; or in another aspect, "substantially all"
as used herein means every segment having a relative abundance of
0.0001 percent or higher. In another particular embodiment, a
repertoire of the invention comprises a set of nucleotide sequences
that encodes substantially all segments of the V(D)J region of a
TCR chain. In another embodiment, a repertoire of the invention
comprises a set of nucleotide sequences having lengths in the range
of from 25-200 nucleotides and including segments of the V, D, and
J regions of a TCR .beta. chain. In another embodiment, a
repertoire of the invention comprises a set of nucleotide sequences
having lengths in the range of from 25-200 nucleotides and
including segments of the V, D, and J regions of an IgH chain. In
another embodiment, a repertoire of the invention comprises a
number of distinct nucleotide sequences that is substantially
equivalent to the number of lymphocytes expressing a distinct IgH
chain. In another embodiment, a repertoire of the invention
comprises a number of distinct nucleotide sequences that is
substantially equivalent to the number of lymphocytes expressing a
distinct TCR .beta. chain. In still another embodiment,
"substantially equivalent" means that with ninety-nine percent
probability a repertoire of nucleotide sequences will include a
nucleotide sequence encoding an IgH or TCR .beta. or portion
thereof carried or expressed by every lymphocyte of a population of
an individual at a frequency of 0.001 percent or greater. In still
another embodiment, "substantially equivalent" means that with
ninety-nine percent probability a repertoire of nucleotide
sequences will include a nucleotide sequence encoding an IgH or TCR
.beta. or portion thereof carried or expressed by every lymphocyte
present at a frequency of 0.0001 percent or greater. The sets of
clonotypes described in the foregoing two sentences are sometimes
referred to herein as representing the "full repertoire" of IgH
and/or TCR.beta. sequences. As mentioned above, when measuring or
generating a clonotype profile (or repertoire profile), a
sufficiently large sample of lymphocytes is obtained so that such
profile provides a reasonably accurate representation of a
repertoire for a particular application. In one aspect, samples
comprising from 10.sup.5 to 10.sup.7 lymphocytes are employed,
especially when obtained from peripheral blood samples of from 1-10
mL.
[0090] "Sequence read" means a sequence of nucleotides determined
from a Sequence or stream of data generated by a sequencing
technique, which determination is made, for example, by means; of
base-calling software associated with the technique, e.g.
base-calling software from a commercial provider of a DNA
sequencing platform. A sequence read usually includes quality
scores for each nucleotide in the sequence. Typically, sequence
reads are made by extending a primer along a template nucleic acid,
e.g. with a DNA polymerase or a DNA ligase. Data is generated by
recording signals, such as optical, chemical (e.g. pH change), or
electrical signals, associated with such extension. Such initial
data is converted into a sequence read.
[0091] "Sequence tree" means a tree data structure for representing
nucleotide sequences. In one aspect, a tree data structure of the
invention is a rooted directed tree comprising nodes and edges that
do not include cycles, or cyclical pathways. Edges from nodes of
tree data structures of the invention are usually ordered. Nodes
and/or edges arc structures that may contain, or be associated
with, a value. Each node in a tree has zero or more child nodes,
which by convention are shown below it in the tree. A node that has
a child is called the child's parent node. A node has at most one
parent. Nodes that do not have any children are called leaf nodes.
The topmost node in a tree is called the root node. Being the
topmost node, the root node will not have parents. It is the node
at which operations on the tree commonly begin (although some
algorithms begin with, the leaf nodes and work up ending at the
root). All other nodes can be reached from it by following edges or
links.
* * * * *